<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83116</article-id><article-id pub-id-type="doi">10.7554/eLife.83116</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group></article-categories><title-group><article-title>Associations of ABO and Rhesus D blood groups with phenome-wide disease incidence: A 41-year retrospective cohort study of 482,914 patients</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-291296"><name><surname>Bruun-Rasmussen</surname><given-names>Peter</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3595-1311</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292618"><name><surname>Hanefeld Dziegiel</surname><given-names>Morten</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8034-1523</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-131179"><name><surname>Banasik</surname><given-names>Karina</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292619"><name><surname>Johansson</surname><given-names>Pär Ingemar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-49326"><name><surname>Brunak</surname><given-names>Søren</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0316-5866</contrib-id><email>soren.brunak@cpr.ku.dk</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05bpbnx46</institution-id><institution>Department of Clinical Immunology, Copenhagen University Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Copenhagen</named-content></addr-line><country>Denmark</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035b05819</institution-id><institution>Novo Nordisk Foundation Center for Protein Research, University of Copenhagen</institution></institution-wrap><addr-line><named-content content-type="city">Copenhagen</named-content></addr-line><country>Denmark</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Boonstra</surname><given-names>Philip</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>University of Michigan</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Franco</surname><given-names>Eduardo L</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>McGill University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>09</day><month>03</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83116</elocation-id><history><date date-type="received" iso-8601-date="2022-08-31"><day>31</day><month>08</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-03-08"><day>08</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-09-26"><day>26</day><month>09</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.09.23.22280292"/></event></pub-history><permissions><copyright-statement>© 2023, Bruun-Rasmussen et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Bruun-Rasmussen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83116-v2.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>Whether natural selection may have attributed to the observed blood group frequency differences between populations remains debatable. The ABO system has been associated with several diseases and recently also with susceptibility to COVID-19 infection. Associative studies of the RhD system and diseases are sparser. A large disease-wide risk analysis may further elucidate the relationship between the ABO/RhD blood groups and disease incidence.</p></sec><sec id="abs2"><title>Methods:</title><p>We performed a systematic log-linear quasi-Poisson regression analysis of the ABO/RhD blood groups across 1,312 phecode diagnoses. Unlike prior studies, we determined the incidence rate ratio for each individual ABO blood group relative to all other ABO blood groups as opposed to using blood group O as the reference. Moreover, we used up to 41 years of nationwide Danish follow-up data, and a disease categorization scheme specifically developed for diagnosis-wide analysis. Further, we determined associations between the ABO/RhD blood groups and the age at the first diagnosis. Estimates were adjusted for multiple testing.</p></sec><sec id="abs3"><title>Results:</title><p>The retrospective cohort included 482,914 Danish patients (60.4% females). The incidence rate ratios (IRRs) of 101 phecodes were found statistically significant between the ABO blood groups, while the IRRs of 28 phecodes were found statistically significant for the RhD blood group. The associations included cancers and musculoskeletal-, genitourinary-, endocrinal-, infectious-, cardiovascular-, and gastrointestinal diseases.</p></sec><sec id="abs4"><title>Conclusions:</title><p>We found associations of disease-wide susceptibility differences between the blood groups of the ABO and RhD systems, including cancer of the tongue, monocytic leukemia, cervical cancer, osteoarthrosis, asthma, and HIV- and hepatitis B infection. We found marginal evidence of associations between the blood groups and the age at first diagnosis.</p></sec><sec id="abs5"><title>Funding:</title><p>Novo Nordisk Foundation and the Innovation Fund Denmark</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>ABO blood groups</kwd><kwd>RhD blood groups</kwd><kwd>phewas</kwd><kwd>disease-wide associations</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100009708</institution-id><institution>Novo Nordisk Fonden</institution></institution-wrap></funding-source><award-id>NNF14CC0001</award-id><principal-award-recipient><name><surname>Brunak</surname><given-names>Søren</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100009708</institution-id><institution>Novo Nordisk Fonden</institution></institution-wrap></funding-source><award-id>NNF17OC0027594</award-id><principal-award-recipient><name><surname>Brunak</surname><given-names>Søren</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012774</institution-id><institution>Innovation Fund Denmark</institution></institution-wrap></funding-source><award-id>5153-00002B</award-id><principal-award-recipient><name><surname>Brunak</surname><given-names>Søren</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The ABO and RhD blood groups are associated with disease-wide susceptibility differences.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Still 100 years after the discovery of the ABO and Rhesus D (RhD) blood group systems, the selective forces that may have attributed to the observed blood group population differences remain elusive (<xref ref-type="bibr" rid="bib2">Anstee, 2010</xref>). The pathophysiological mechanisms behind the observed relationship between blood groups and diseases are not well understood either. The ABO system has been associated with susceptibility to multiple diseases, including gastrointestinal- and cardiovascular diseases and pancreatic-, gastric-, and ovarian cancers (<xref ref-type="bibr" rid="bib27">Vasan et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Liumbruno and Franchini, 2014</xref>; <xref ref-type="bibr" rid="bib30">Wolpin et al., 2010</xref>; <xref ref-type="bibr" rid="bib15">Groot et al., 2020</xref>; <xref ref-type="bibr" rid="bib11">Edgren et al., 2010</xref>; <xref ref-type="bibr" rid="bib7">Dahlén et al., 2021</xref>; <xref ref-type="bibr" rid="bib19">Li and Schooling, 2020</xref>). The ABO system has also been associated with the susceptibility, progression, and severity of COVID-19 (<xref ref-type="bibr" rid="bib12">Ellinghaus et al., 2020</xref>). In contrast, apart from hemolytic disease of the newborn, reported associations between the RhD blood group and disease development are sparser (<xref ref-type="bibr" rid="bib2">Anstee, 2010</xref>).</p><p>Specifically, higher levels of factor VIII (FVIII) and von Willebrand factor (vWF) observed in individuals with a non-O blood group have been suggested to affect the development of cardiovascular disease (<xref ref-type="bibr" rid="bib16">Jenkins and O’Donnell, 2006</xref>; <xref ref-type="bibr" rid="bib14">Franchini and Lippi, 2015</xref>). Additionally, blood group-related antigens have been suggested to be involved in the adhesion of trophoblast, inflammatory cells, and metastatic tumor cells to the endothelial cells of the vasculature (<xref ref-type="bibr" rid="bib25">Ravn and Dabelsteen, 2000</xref>). The endothelial cells of the vasculature have also been suggested to contribute to the initiation and propagation of severe clinical manifestations of COVID-19 (<xref ref-type="bibr" rid="bib26">Teuwen et al., 2020</xref>).</p><p>Recently, an associative disease-wide risk analysis of the ABO and RhD blood groups was conducted in a large Swedish cohort (<xref ref-type="bibr" rid="bib7">Dahlén et al., 2021</xref>). The study generated further support for previous findings and suggested new associations. Here, we further uncover the relationship between the ABO and RhD blood groups and disease susceptibility using a Danish cohort of 482,914 patients. In contrast to previous studies, we use up to 41 years of follow-up data, and a disease categorization scheme specifically developed for disease-wide analysis called phecodes (<xref ref-type="bibr" rid="bib31">Wu et al., 2019</xref>). Further, we determine the uniqueness of each individual ABO blood group as opposed to using blood group O as the reference.</p><p>We estimate incidence rate ratios of 1312 phecodes (diagnoses) for the ABO and RhD blood groups. Further, we determine associations between the ABO/RhD blood groups and the age at the first diagnosis to better disclose the temporal life course element of disease development.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Study design</title><p>This retrospective cohort study was based on the integration of the Danish National Patient Registry (DNPR) and data on ABO/RhD blood groups of hospitalized patients. We included Danish patients who had their ABO/RhD blood group determined in the Capital Region or Region Zealand (covering ~45% of the Danish population <xref ref-type="bibr" rid="bib22">Nordjylland, 2022</xref>), between January 1, 2006, and April 10, 2018. A blood type determination is commonly done for patients who may require a blood transfusion during hospitalization for example, anemic patients and women in labor. In the inclusion period, approximately 90% of the population in the Capital Region and 97% of the Region Zealand population were of European ancestry (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). The DNPR provided the International Classification of Diseases 8<sup>th</sup> and 10<sup>th</sup> revision (ICD-8 and ICD-10) diagnosis codes, dates of diagnosis, date of birth, date of potential emigration, and sex of patients, with records dating back to 1977.</p><p>Similar to a case-control study, the patients were included retrospectively. Here, selection into the study was based on an in-hospital ABO/RhD blood group determination. That is, the person-time and the entire disease history back to 1977 of patients hospitalized between 2006 and 2018 with known ABO/RhD blood groups were included retrospectively.</p><p>We defined diseased and non-diseased individuals using the phecode mapping from ICD-10 diagnosis codes (<xref ref-type="bibr" rid="bib31">Wu et al., 2019</xref>). Before categorizing the assigned ICD diagnosis codes into phecodes, the ICD-8 codes were converted to ICD-10 codes (<xref ref-type="bibr" rid="bib23">Pedersen et al., 2023</xref>). Further, referral diagnoses were excluded. Pregnancy- and perinatal diagnosis (ICD-10 chapters 15–16) assigned before or after age 10 were excluded, or, when possible, rightly assigned to the mother or newborn, respectively. The disease categories of injuries, poisonings, and symptoms were deemed unlikely to be associated with the blood groups and excluded from the analyses (phecode categories: ‘injuries and poisonings’, ‘symptoms’ and phecodes above 999). Only phecodes with at least 100 cases in the study sample were included. The patients were followed from the entry in the DNPR to the date of death, emigration, the first event of the studied phecode, or end study period (April 10, 2018), whichever came first. Thus, follow-up was up to 41 years. The patients were allowed to contribute events and time at risk to multiple phecode analysis.</p></sec><sec id="s2-2"><title>Diagnosis-wide incidence rate ratios</title><p>We used a log-linear quasi-Poisson regression model to estimate incidence rate ratios (IRRs) of each phecode among individuals with blood groups A, B, AB, and O relative to the other blood groups, respectively (e.g. A vs. B, AB, and O) (<xref ref-type="bibr" rid="bib10">Dewey et al., 1995</xref>; <xref ref-type="bibr" rid="bib28">Ver Hoef and Boveng, 2007</xref>). Further, we compared individuals with positive RhD type relative to negative RhD type. The analyses of diseases developed by both males and females were adjusted for sex, while analyses of sex-restricted diseases (e.g. cervical cancer) only included a subgroup of individuals of the restricted sex. Sex-restricted diseases were pre-defined by the phecode terminology. Sex was adjusted for as prior studies have found sex differences in the incidence rates of multiple diseases (<xref ref-type="bibr" rid="bib29">Westergaard et al., 2019</xref>). Further, we adjusted for the year of birth and attained age, both modeled using restricted cubic splines with five knots. Attained age was split into 1 year intervals and treated as a time-dependent covariate, thus allowing individuals to move between categories with time. Herewith, age was used as the underlying time scale. Further, an interaction between attained age and sex was modeled for non-sex-restricted analyses. Patients were excluded from the analysis if they were assigned the phecode under study at the start of the DNPR. For analysis of congenital phecodes (e.g. sickle cell disease), prevalence ratios were estimated instead of IRRs by using the cohort size as the offset (see <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> for a list of the congenital phecodes). The analyses of ABO blood groups were adjusted for RhD type, and the RhD-analyses were adjusted for the ABO blood group. Adjustment for the birth year was done to control for societal changes and was used instead of the calendar period of diagnosis. The robust quasi-Poisson variance formula was used to control for over-dispersion (<xref ref-type="bibr" rid="bib28">Ver Hoef and Boveng, 2007</xref>). We conducted a supplemental analysis using the same methodology but where blood group O was instead used as the reference to enable direct comparison and meta-analysis with previous studies.</p></sec><sec id="s2-3"><title>Age of first hospital diagnosis</title><p>We estimated differences in age of first phecode of individuals with blood group A, B, AB, and O relative to any other blood group, respectively. Similar analyses were done for RhD-positive individuals relative to RhD negative individuals. We used a linear regression model adjusted for sex and birth year (as a restricted cubic spline with five knots). Analysis of sex-restricted phecodes was not adjusted for sex. Individuals who were assigned the studied phecode at the start date of the DNPR were excluded as the age of diagnosis was uncertain. Further, congenital- and pregnancy-related phecodes were not included.</p><p>Statistical analyses were performed in R (version 3.6.2) using the survival and rms package. p-values were two-sided. p-values and confidence intervals were adjusted for multiple testing by the false discovery rate (FDR) approach, accounting for the number of performed tests (5 blood groups times 1312 phecodes; <xref ref-type="bibr" rid="bib5">Benjamini and Hochberg, 1995</xref>; <xref ref-type="bibr" rid="bib1">Altman and Bland, 2011</xref>). FDR adjusted p-values &lt;0.05 were deemed statistically significant. The analysis pipeline was made in python (anaconda3/5.3.0) using snakemake for reproducibility (<xref ref-type="bibr" rid="bib17">Köster and Rahmann, 2012</xref>). The analyses code is available through <ext-link ext-link-type="uri" xlink:href="https://www.github.com/peterbruun/blood_type_study">https://www.github.com/peterbruun/blood_type_study</ext-link> (copy archived at <xref ref-type="bibr" rid="bib6">Bruun-Rasmussen, 2023</xref>). The manuscript complies with the STROBE reporting guidelines.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><p>In total, 482,914patients (60.4%females) were included and 1312 phecodes (diagnosis codes) were examined (<xref ref-type="fig" rid="fig1">Figure 1</xref>, and <xref ref-type="table" rid="table1">Table 1</xref>). The median follow-up time for all phecode analyses was 17,555,322 person-years (Q1-Q3: 17,324,597–17,615,142). The cohort held a wide age distribution of patients born from 1901 to 2015 (<xref ref-type="table" rid="table1">Table 1</xref>, and <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). The ABO/RhD blood group distribution of the patients was similar to that of a previously summarized reference population of 2.2 million Danes (<xref ref-type="table" rid="table1">Table 1</xref>; <xref ref-type="bibr" rid="bib4">Barnkob et al., 2020</xref>; <xref ref-type="bibr" rid="bib3">Banks, 2022</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Selection of patients for the 41-year retrospective cohort study on ABO/RhD blood groups and associations with disease incidence in 482,914 Danish patients.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83116-fig1-v2.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Characteristics of patients in the 41-year retrospective cohort study on ABO/RhD blood groups and associations with disease incidence in 482,914 Danish patients.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="center" valign="bottom">N=482,914</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="4"><bold>ABO, n (%</bold>)</td><td align="center" valign="bottom"><bold>O</bold></td><td align="center" valign="bottom">197,634 (40.9)</td></tr><tr><td align="center" valign="bottom"><bold>A</bold></td><td align="center" valign="bottom">206,110 (42.7)</td></tr><tr><td align="center" valign="bottom"><bold>AB</bold></td><td align="center" valign="bottom">22,111 (4.6)</td></tr><tr><td align="center" valign="bottom"><bold>B</bold></td><td align="center" valign="bottom">57,059 (11.8)</td></tr><tr><td align="left" valign="bottom" rowspan="2"><bold>RhD, n (%</bold>)</td><td align="center" valign="bottom"><bold>Negative</bold></td><td align="center" valign="bottom">74,150 (15.4)</td></tr><tr><td align="center" valign="bottom"><bold>Positive</bold></td><td align="center" valign="bottom">408,764 (84.6)</td></tr><tr><td align="left" valign="bottom" rowspan="2"><bold>Sex, n (%</bold>)</td><td align="center" valign="bottom"><bold>K</bold></td><td align="center" valign="bottom">291,649 (60.4)</td></tr><tr><td align="center" valign="bottom"><bold>M</bold></td><td align="center" valign="bottom">191,265 (39.6)</td></tr><tr><td align="left" valign="bottom"><bold>Birth year, median [Q1,Q3]</bold></td><td align="center" valign="bottom"/><td align="center" valign="bottom">1963 [1945,1982]</td></tr><tr><td align="left" valign="bottom"><bold>Age at entry, median [Q1,Q3]</bold></td><td align="center" valign="bottom"/><td align="center" valign="bottom">13 [0,32]</td></tr><tr><td align="left" valign="bottom"><bold>Follow-up time, median [Q1,Q3]</bold></td><td align="center" valign="bottom"/><td align="center" valign="bottom">40.8 [33.4,41.3]</td></tr></tbody></table></table-wrap><sec id="s3-1"><title>Incidence rate ratios</title><p>After adjustment for multiple testing, we found the incidence rate ratios (IRRs) of 101 and 28 phecodes (116 unique) to be statistically significant for the ABO and RhD blood groups, respectively. The statistically significant IRRs are given with 95% confidence intervals in <xref ref-type="table" rid="table2">Table 2</xref>. The estimates of all examined phecodes are given in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>. Further, Manhattan plots of the p-values and disease categories are presented in <xref ref-type="fig" rid="fig2">Figures 2</xref>—<xref ref-type="fig" rid="fig6">6</xref> .</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Manhattan plot for blood group A with phecodes included by category.</title><p>The vertical axis shows the -log10 transformed FDR adjusted p-values on a log10-scale. The horizontal axis shows the phecodes by category. The red line indicates the statistically significant level of &lt;0.05 for FDR adjusted p-values. Associations with p-value &gt;0.8 are not displayed. Coloured and annotated associations were deemed statistically significant. The direction of the triangles indicates positive or inverse associations (upward: IRR &gt;1, downward: IRR &lt;1). The size of the triangles indicates the size of the incidence rate ratio.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83116-fig2-v2.tif"/></fig><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Manhattan plot for blood group B with phecodes included by category.</title><p>The vertical axis shows the -log10 transformed FDR adjusted p-values on a log10-scale. The horizontal axis shows the phecodes by category. The red line indicates the statistically significant level of &lt;0.05 for FDR adjusted p-values. Associations with p-value &gt;0.8 are not displayed. Coloured and annotated associations were deemed statistically significant. The direction of the triangles indicates positive or inverse associations (upward: IRR &gt;1, downward: IRR &lt;1). The size of the triangles indicates the size of the incidence rate ratio.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83116-fig3-v2.tif"/></fig><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Manhattan plot for blood group AB with phecodes included by category.</title><p>The vertical axis shows the -log10 transformed FDR adjusted p-values on a log10-scale. The horizontal axis shows the phecodes by category. The red line indicates the statistically significant level of &lt;0.05 for FDR adjusted p-values. Associations with p-value &gt;0.8 are not displayed. Coloured and annotated associations were deemed statistically significant. The direction of the triangles indicates positive or inverse associations (upward: IRR &gt;1, downward: IRR &lt;1). The size of the triangles indicates the size of the incidence rate ratio.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83116-fig4-v2.tif"/></fig><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Manhattan plot for blood group O with phecodes included by category.</title><p>The vertical axis shows the -log10 transformed FDR adjusted p-values on a log10-scale. The horizontal axis shows the phecodes by category. The red line indicates the statistically significant level of &lt;0.05 for FDR adjusted p-values. Associations with p-value &gt;0.8 are not displayed. Coloured and annotated associations were deemed statistically significant. The direction of the triangles indicates positive or inverse associations (upward: IRR &gt;1, downward: IRR &lt;1). The size of the triangles indicates the size of the incidence rate ratio.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83116-fig5-v2.tif"/></fig><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Manhattan plot for the Rhesus D blood group with phecodes included by category.</title><p>The vertical axis shows the -log10 transformed FDR adjusted p-values on a log10-scale. The horizontal axis shows the phecodes by category. The red line indicates the statistically significant level of &lt;0.05 for FDR adjusted p-values. Associations with p-value &gt;0.8 are not displayed. Coloured and annotated associations were deemed statistically significant. The direction of the triangles indicates positive or inverse associations (upward: IRR &gt;1, downward: IRR &lt;1). The size of the triangles indicates the size of the incidence rate ratio.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83116-fig6-v2.tif"/></fig><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Statistically significant incidence rate ratios for each individual blood group A, B, AB, and O relative to any other blood group (e.g. A vs. B, AB, and O combined). Further, also for RhD-positive blood group relative to the RhD negative blood group.</title><p><supplementary-material id="table2sdata1"><label>Table 2—source data 1.</label><caption><title>Associations between the ABO/RhD blood groups and phecode incidence rate ratios.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83116-table2-data1-v2.zip"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="4"/><th align="left" valign="bottom" colspan="2">Blood group A</th><th align="left" valign="bottom" colspan="2">Blood group B</th><th align="left" valign="bottom" colspan="2">Blood group AB</th><th align="left" valign="bottom" colspan="2">Blood group 0</th><th align="left" valign="bottom" colspan="2">Blood group RhD</th></tr><tr><th align="left" valign="bottom">Phecode</th><th align="left" valign="bottom">Phenotype</th><th align="left" valign="bottom">Cases</th><th align="left" valign="bottom">Person-years</th><th align="left" valign="bottom">IRR (95% CI)</th><th align="left" valign="bottom">p-value</th><th align="left" valign="bottom">IRR (95% CI)</th><th align="left" valign="bottom">p-value</th><th align="left" valign="bottom">IRR (95% CI)</th><th align="left" valign="bottom">p-value</th><th align="left" valign="bottom">IRR (95% CI)</th><th align="left" valign="bottom">p-value</th><th align="left" valign="bottom">IRR (95% CI)</th><th align="left" valign="bottom">p-value</th></tr></thead><tbody><tr><td colspan="14" style="author-callout-style-b8"><bold>Infectious Diseases</bold></td></tr><tr><td align="char" char="." valign="bottom">010</td><td align="left" valign="bottom">Tuberculosis</td><td align="char" char="." valign="bottom">2101</td><td align="char" char="." valign="bottom">17603440</td><td align="left" valign="bottom">0.87 (0.74, 1.02)</td><td align="char" char="." valign="bottom">0.093</td><td align="char" char="." valign="bottom"><bold>1.4 (1.18, 1.65</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">1.07 (0.32, 3.57)</td><td align="char" char="." valign="bottom">0.915</td><td align="char" char="." valign="bottom">0.97 (0.59, 1.57)</td><td align="char" char="." valign="bottom">0.899</td><td align="char" char="." valign="bottom"><bold>1.36 (1.12, 1.65</bold>)</td><td align="char" char="." valign="bottom"><bold>0.002</bold></td></tr><tr><td align="char" char="." valign="bottom">070</td><td align="left" valign="bottom">Viral hepatitis</td><td align="char" char="." valign="bottom">6596</td><td align="char" char="." valign="bottom">17557078</td><td align="left" valign="bottom"><bold>0.88 (0.82, 0.93</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom"><bold>1.22 (1.12, 1.34</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">1 (0.81, 1.23)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">1.04 (0.9, 1.21)</td><td align="char" char="." valign="bottom">0.583</td><td align="char" char="." valign="bottom">1.12 (0.99, 1.28)</td><td align="char" char="." valign="bottom">0.069</td></tr><tr><td align="char" char="." valign="bottom">070.2</td><td align="left" valign="bottom">Viral hepatitis B</td><td align="char" char="." valign="bottom">1664</td><td align="char" char="." valign="bottom">17613572</td><td align="left" valign="bottom"><bold>0.7 (0.62, 0.79</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom"><bold>1.66 (1.46, 1.9</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">1.12 (0.38, 3.26)</td><td align="char" char="." valign="bottom">0.851</td><td align="char" char="." valign="bottom">1.06 (0.7, 1.61)</td><td align="char" char="." valign="bottom">0.794</td><td align="char" char="." valign="bottom"><bold>1.36 (1.07, 1.71</bold>)</td><td align="char" char="." valign="bottom"><bold>0.01</bold></td></tr><tr><td align="char" char="." valign="bottom">071</td><td align="left" valign="bottom">Human immunodeficiency virus [HIV] disease</td><td align="char" char="." valign="bottom">1182</td><td align="char" char="." valign="bottom">17620808</td><td align="left" valign="bottom">0.81 (0.63, 1.05)</td><td align="char" char="." valign="bottom">0.109</td><td align="char" char="." valign="bottom">1.18 (0.54, 2.59)</td><td align="char" char="." valign="bottom">0.688</td><td align="left" valign="bottom">1.19 (0.52, 2.73)</td><td align="char" char="." valign="bottom">0.693</td><td align="char" char="." valign="bottom">1.1 (0.67, 1.81)</td><td align="char" char="." valign="bottom">0.725</td><td align="char" char="." valign="bottom"><bold>1.49 (1.04, 2.15</bold>)</td><td align="char" char="." valign="bottom"><bold>0.031</bold></td></tr><tr><td align="char" char="." valign="bottom">071.1</td><td align="left" valign="bottom">HIV infection, symptomatic</td><td align="char" char="." valign="bottom">1182</td><td align="char" char="." valign="bottom">17620808</td><td align="left" valign="bottom">0.81 (0.63, 1.05)</td><td align="char" char="." valign="bottom">0.109</td><td align="char" char="." valign="bottom">1.18 (0.54, 2.59)</td><td align="char" char="." valign="bottom">0.688</td><td align="left" valign="bottom">1.19 (0.52, 2.73)</td><td align="char" char="." valign="bottom">0.693</td><td align="char" char="." valign="bottom">1.1 (0.67, 1.81)</td><td align="char" char="." valign="bottom">0.725</td><td align="char" char="." valign="bottom"><bold>1.49 (1.04, 2.15</bold>)</td><td align="char" char="." valign="bottom"><bold>0.031</bold></td></tr><tr><td align="char" char="." valign="bottom">110.13</td><td align="left" valign="bottom">Dermatophytosis of the body</td><td align="char" char="." valign="bottom">211</td><td align="char" char="." valign="bottom">17630531</td><td align="left" valign="bottom">0.89 (0.35, 2.22)</td><td align="char" char="." valign="bottom">0.809</td><td align="char" char="." valign="bottom"><bold>1.64 (1.08, 2.49</bold>)</td><td align="char" char="." valign="bottom"><bold>0.02</bold></td><td align="left" valign="bottom">0.93 (0.03, 30.15)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.88 (0.35, 2.23)</td><td align="char" char="." valign="bottom">0.804</td><td align="char" char="." valign="bottom">1.13 (0.2, 6.46)</td><td align="char" char="." valign="bottom">0.897</td></tr><tr><td colspan="14" style="author-callout-style-b8"><bold>Neoplasms</bold></td></tr><tr><td align="char" char="." valign="bottom">145.2</td><td align="left" valign="bottom">Cancer of tongue</td><td align="char" char="." valign="bottom">606</td><td align="char" char="." valign="bottom">17629055</td><td align="left" valign="bottom">0.95 (0.51, 1.76)</td><td align="char" char="." valign="bottom">0.877</td><td align="char" char="." valign="bottom">1.13 (0.71, 1.82)</td><td align="char" char="." valign="bottom">0.616</td><td align="left" valign="bottom">1.21 (0.43, 3.38)</td><td align="char" char="." valign="bottom">0.726</td><td align="char" char="." valign="bottom">0.96 (0.46, 2.03)</td><td align="char" char="." valign="bottom">0.93</td><td align="char" char="." valign="bottom"><bold>0.74 (0.6, 0.92</bold>)</td><td align="char" char="." valign="bottom"><bold>0.007</bold></td></tr><tr><td align="char" char="." valign="bottom">157</td><td align="left" valign="bottom">Pancreatic cancer</td><td align="char" char="." valign="bottom">2828</td><td align="char" char="." valign="bottom">17627948</td><td align="left" valign="bottom"><bold>1.26 (1.16, 1.36</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.02 (0.34, 3.13)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom">1.11 (0.53, 2.33)</td><td align="char" char="." valign="bottom">0.8</td><td align="char" char="." valign="bottom"><bold>0.76 (0.7, 0.82</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.01 (0.52, 1.98)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">180</td><td align="left" valign="bottom">Cervical cancer and dysplasia</td><td align="char" char="." valign="bottom">12538</td><td align="char" char="." valign="bottom">10308860</td><td align="left" valign="bottom">1.05 (0.99, 1.12)</td><td align="char" char="." valign="bottom">0.118</td><td align="char" char="." valign="bottom"><bold>0.9 (0.83, 0.97</bold>)</td><td align="char" char="." valign="bottom"><bold>0.01</bold></td><td align="left" valign="bottom">0.96 (0.66, 1.39)</td><td align="char" char="." valign="bottom">0.839</td><td align="char" char="." valign="bottom">1 (0.99, 1.01)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.93 (0.86, 1.01)</td><td align="char" char="." valign="bottom">0.083</td></tr><tr><td align="char" char="." valign="bottom">180.3</td><td align="left" valign="bottom">Cervical intraepithelial neoplasia [CIN] [Cervical dysplasia]</td><td align="char" char="." valign="bottom">10895</td><td align="char" char="." valign="bottom">10327107</td><td align="left" valign="bottom">1.06 (0.99, 1.13)</td><td align="char" char="." valign="bottom">0.115</td><td align="char" char="." valign="bottom"><bold>0.89 (0.82, 0.97</bold>)</td><td align="char" char="." valign="bottom"><bold>0.009</bold></td><td align="left" valign="bottom">0.95 (0.67, 1.34)</td><td align="char" char="." valign="bottom">0.766</td><td align="char" char="." valign="bottom">1 (0.84, 1.19)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.93 (0.85, 1.01)</td><td align="char" char="." valign="bottom">0.102</td></tr><tr><td align="char" char="." valign="bottom">195.1</td><td align="left" valign="bottom">Malignant neoplasm, other</td><td align="char" char="." valign="bottom">7383</td><td align="char" char="." valign="bottom">17603424</td><td align="left" valign="bottom">0.96 (0.87, 1.05)</td><td align="char" char="." valign="bottom">0.368</td><td align="char" char="." valign="bottom">0.95 (0.77, 1.17)</td><td align="char" char="." valign="bottom">0.642</td><td align="left" valign="bottom">0.96 (0.55, 1.69)</td><td align="char" char="." valign="bottom">0.906</td><td align="char" char="." valign="bottom"><bold>1.07 (1, 1.15</bold>)</td><td align="char" char="." valign="bottom"><bold>0.038</bold></td><td align="char" char="." valign="bottom"><bold>0.88 (0.82, 0.94</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="char" char="." valign="bottom">204.3</td><td align="left" valign="bottom">Monocytic leukemia</td><td align="char" char="." valign="bottom">179</td><td align="char" char="." valign="bottom">17631300</td><td align="left" valign="bottom">1.04 (0.15, 7.27)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.92 (0.06, 13.67)</td><td align="char" char="." valign="bottom">0.957</td><td align="left" valign="bottom"><bold>0.25 (0.06, 0.98</bold>)</td><td align="char" char="." valign="bottom"><bold>0.047</bold></td><td align="char" char="." valign="bottom">1.13 (0.44, 2.91)</td><td align="char" char="." valign="bottom">0.809</td><td align="char" char="." valign="bottom">0.84 (0.37, 1.93)</td><td align="char" char="." valign="bottom">0.698</td></tr><tr><td align="char" char="." valign="bottom">216</td><td align="left" valign="bottom">Benign neoplasm of skin</td><td align="char" char="." valign="bottom">12993</td><td align="char" char="." valign="bottom">17495431</td><td align="left" valign="bottom">1.02 (0.84, 1.23)</td><td align="char" char="." valign="bottom">0.883</td><td align="char" char="." valign="bottom"><bold>0.9 (0.82, 0.98</bold>)</td><td align="char" char="." valign="bottom"><bold>0.014</bold></td><td align="left" valign="bottom">0.99 (0.62, 1.57)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">1.03 (0.93, 1.14)</td><td align="char" char="." valign="bottom">0.583</td><td align="char" char="." valign="bottom">0.95 (0.85, 1.05)</td><td align="char" char="." valign="bottom">0.32</td></tr><tr><td align="char" char="." valign="bottom">860</td><td align="left" valign="bottom">Bone marrow or stem cell transplant</td><td align="char" char="." valign="bottom">142</td><td align="char" char="." valign="bottom">17631302</td><td align="left" valign="bottom">1.01 (0.77, 1.31)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.63 (0.15, 2.57)</td><td align="char" char="." valign="bottom">0.531</td><td align="left" valign="bottom"><bold>0.15 (0.05, 0.44</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom"><bold>1.37 (1.02, 1.82</bold>)</td><td align="char" char="." valign="bottom"><bold>0.033</bold></td><td align="char" char="." valign="bottom"><bold>4.15 (2.13, 8.09</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td colspan="14" style="author-callout-style-b8"><bold>Endocrine/Metabolic</bold></td></tr><tr><td align="char" char="." valign="bottom">242</td><td align="left" valign="bottom">Thyrotoxicosis with or without goiter</td><td align="char" char="." valign="bottom">9744</td><td align="char" char="." valign="bottom">17527426</td><td align="left" valign="bottom">0.93 (0.86, 1.02)</td><td align="char" char="." valign="bottom">0.127</td><td align="char" char="." valign="bottom">0.99 (0.59, 1.65)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom">0.9 (0.66, 1.22)</td><td align="char" char="." valign="bottom">0.505</td><td align="char" char="." valign="bottom"><bold>1.09 (1.02, 1.18</bold>)</td><td align="char" char="." valign="bottom"><bold>0.013</bold></td><td align="char" char="." valign="bottom">1.02 (0.7, 1.48)</td><td align="char" char="." valign="bottom">0.927</td></tr><tr><td align="char" char="." valign="bottom">250</td><td align="left" valign="bottom">Diabetes mellitus</td><td align="char" char="." valign="bottom">36810</td><td align="char" char="." valign="bottom">17295033</td><td align="left" valign="bottom">1.01 (0.92, 1.11)</td><td align="char" char="." valign="bottom">0.849</td><td align="char" char="." valign="bottom"><bold>1.09 (1.05, 1.13</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">1.06 (0.95, 1.18)</td><td align="char" char="." valign="bottom">0.32</td><td align="char" char="." valign="bottom"><bold>0.95 (0.92, 0.97</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom"><bold>1.07 (1.03, 1.11</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="char" char="." valign="bottom">250.2</td><td align="left" valign="bottom">Type 2 diabetes</td><td align="char" char="." valign="bottom">32505</td><td align="char" char="." valign="bottom">17346533</td><td align="left" valign="bottom">1 (0.82, 1.23)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom"><bold>1.1 (1.06, 1.15</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">1.07 (0.96, 1.19)</td><td align="char" char="." valign="bottom">0.213</td><td align="char" char="." valign="bottom"><bold>0.94 (0.92, 0.97</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom"><bold>1.07 (1.02, 1.12</bold>)</td><td align="char" char="." valign="bottom"><bold>0.004</bold></td></tr><tr><td align="char" char="." valign="bottom">261</td><td align="left" valign="bottom">Vitamin deficiency</td><td align="char" char="." valign="bottom">6674</td><td align="char" char="." valign="bottom">17594082</td><td align="left" valign="bottom">0.94 (0.86, 1.03)</td><td align="char" char="." valign="bottom">0.183</td><td align="char" char="." valign="bottom"><bold>1.15 (1.05, 1.26</bold>)</td><td align="char" char="." valign="bottom"><bold>0.003</bold></td><td align="left" valign="bottom">0.93 (0.66, 1.31)</td><td align="char" char="." valign="bottom">0.683</td><td align="char" char="." valign="bottom">1.01 (0.75, 1.36)</td><td align="char" char="." valign="bottom">0.94</td><td align="char" char="." valign="bottom">1.06 (0.92, 1.22)</td><td align="char" char="." valign="bottom">0.405</td></tr><tr><td align="char" char="." valign="bottom">261.4</td><td align="left" valign="bottom">Vitamin D deficiency</td><td align="char" char="." valign="bottom">4105</td><td align="char" char="." valign="bottom">17613013</td><td align="left" valign="bottom"><bold>0.91 (0.85, 0.97</bold>)</td><td align="char" char="." valign="bottom"><bold>0.007</bold></td><td align="char" char="." valign="bottom"><bold>1.23 (1.14, 1.34</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">0.95 (0.56, 1.61)</td><td align="char" char="." valign="bottom">0.86</td><td align="char" char="." valign="bottom">1.01 (0.63, 1.63)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom"><bold>1.14 (1.04, 1.25</bold>)</td><td align="char" char="." valign="bottom"><bold>0.006</bold></td></tr><tr><td align="char" char="." valign="bottom">271</td><td align="left" valign="bottom">Disorders of carbohydrate transport and metabolism</td><td align="char" char="." valign="bottom">1306</td><td align="char" char="." valign="bottom">17619038</td><td align="left" valign="bottom">0.86 (0.69, 1.07)</td><td align="char" char="." valign="bottom">0.176</td><td align="char" char="." valign="bottom"><bold>1.28 (1, 1.64</bold>)</td><td align="char" char="." valign="bottom"><bold>0.047</bold></td><td align="left" valign="bottom">1.07 (0.23, 4.92)</td><td align="char" char="." valign="bottom">0.934</td><td align="char" char="." valign="bottom">1.01 (0.51, 2)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">1.16 (0.78, 1.72)</td><td align="char" char="." valign="bottom">0.475</td></tr><tr><td align="char" char="." valign="bottom">271.3</td><td align="left" valign="bottom">Intestinal disaccharidase deficiencies and disaccharide malabsorption</td><td align="char" char="." valign="bottom">1154</td><td align="char" char="." valign="bottom">17621337</td><td align="left" valign="bottom">0.85 (0.68, 1.05)</td><td align="char" char="." valign="bottom">0.135</td><td align="char" char="." valign="bottom"><bold>1.32 (1.05, 1.67</bold>)</td><td align="char" char="." valign="bottom"><bold>0.018</bold></td><td align="left" valign="bottom">1.08 (0.24, 4.88)</td><td align="char" char="." valign="bottom">0.924</td><td align="char" char="." valign="bottom">1.01 (0.55, 1.86)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">1.15 (0.73, 1.8)</td><td align="char" char="." valign="bottom">0.562</td></tr><tr><td align="char" char="." valign="bottom">272</td><td align="left" valign="bottom">Disorders of lipoid metabolism</td><td align="char" char="." valign="bottom">41222</td><td align="char" char="." valign="bottom">17347032</td><td align="left" valign="bottom"><bold>1.06 (1.03, 1.09</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.01 (0.72, 1.42)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom">1.03 (0.63, 1.69)</td><td align="char" char="." valign="bottom">0.92</td><td align="char" char="." valign="bottom"><bold>0.93 (0.91, 0.96</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.02 (0.9, 1.17)</td><td align="char" char="." valign="bottom">0.733</td></tr><tr><td align="char" char="." valign="bottom">272.11</td><td align="left" valign="bottom">Hypercholesterolemia</td><td align="char" char="." valign="bottom">35565</td><td align="char" char="." valign="bottom">17395012</td><td align="left" valign="bottom"><bold>1.06 (1.03, 1.09</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.01 (0.79, 1.29)</td><td align="char" char="." valign="bottom">0.956</td><td align="left" valign="bottom">1.03 (0.88, 1.21)</td><td align="char" char="." valign="bottom">0.709</td><td align="char" char="." valign="bottom"><bold>0.93 (0.91, 0.96</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.03 (0.96, 1.09)</td><td align="char" char="." valign="bottom">0.433</td></tr><tr><td align="char" char="." valign="bottom">272.13</td><td align="left" valign="bottom">Mixed hyperlipidemia</td><td align="char" char="." valign="bottom">1324</td><td align="char" char="." valign="bottom">17619911</td><td align="left" valign="bottom">1.05 (0.66, 1.67)</td><td align="char" char="." valign="bottom">0.841</td><td align="char" char="." valign="bottom">1.04 (0.14, 7.94)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom"><bold>1.39 (1.01, 1.91</bold>)</td><td align="char" char="." valign="bottom"><bold>0.04</bold></td><td align="char" char="." valign="bottom">0.87 (0.7, 1.08)</td><td align="char" char="." valign="bottom">0.211</td><td align="char" char="." valign="bottom">1.09 (0.58, 2.04)</td><td align="char" char="." valign="bottom">0.809</td></tr><tr><td colspan="14" style="author-callout-style-b8"><bold>Hematopoietic</bold></td></tr><tr><td align="char" char="." valign="bottom">282</td><td align="left" valign="bottom">Hereditary hemolytic anemias</td><td align="char" char="." valign="bottom">947</td><td align="char" char="." valign="bottom">482914*</td><td align="left" valign="bottom"><bold>0.76 (0.59, 0.99)**</bold></td><td align="char" char="." valign="bottom"><bold>0.039</bold></td><td align="char" char="." valign="bottom">1.36 (0.9, 2.06)**</td><td align="char" char="." valign="bottom">0.141</td><td align="left" valign="bottom">1.42 (0.72, 2.8)**</td><td align="char" char="." valign="bottom">0.316</td><td align="char" char="." valign="bottom">1.03 (0.25, 4.26)**</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom"><bold>1.65 (1.06, 2.56)**</bold></td><td align="char" char="." valign="bottom"><bold>0.026</bold></td></tr><tr><td align="char" char="." valign="bottom">282.8</td><td align="left" valign="bottom">Other hemoglobinopathies</td><td align="char" char="." valign="bottom">557</td><td align="char" char="." valign="bottom">482914*</td><td align="left" valign="bottom"><bold>0.65 (0.51, 0.82)**</bold></td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom"><bold>1.56 (1.16, 2.1)**</bold></td><td align="char" char="." valign="bottom"><bold>0.003</bold></td><td align="left" valign="bottom">1.47 (0.77, 2.83)**</td><td align="char" char="." valign="bottom">0.248</td><td align="char" char="." valign="bottom">1.09 (0.58, 2.07)**</td><td align="char" char="." valign="bottom">0.798</td><td align="char" char="." valign="bottom"><bold>2.24 (1.52, 3.29)**</bold></td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="char" char="." valign="bottom">286</td><td align="left" valign="bottom">Coagulation defects</td><td align="char" char="." valign="bottom">4124</td><td align="char" char="." valign="bottom">17606796</td><td align="left" valign="bottom"><bold>1.14 (1.01, 1.3</bold>)</td><td align="char" char="." valign="bottom"><bold>0.035</bold></td><td align="char" char="." valign="bottom">0.95 (0.56, 1.6)</td><td align="char" char="." valign="bottom">0.854</td><td align="left" valign="bottom">1.14 (0.67, 1.95)</td><td align="char" char="." valign="bottom">0.633</td><td align="char" char="." valign="bottom"><bold>0.87 (0.76, 0.99</bold>)</td><td align="char" char="." valign="bottom"><bold>0.029</bold></td><td align="char" char="." valign="bottom">0.93 (0.66, 1.33)</td><td align="char" char="." valign="bottom">0.717</td></tr><tr><td align="char" char="." valign="bottom">286.11</td><td align="left" valign="bottom">Von willebrand’s disease</td><td align="char" char="." valign="bottom">214</td><td align="char" char="." valign="bottom">482914*</td><td align="left" valign="bottom">0.71 (0.35, 1.47)**</td><td align="char" char="." valign="bottom">0.368</td><td align="char" char="." valign="bottom">0.49 (0.17, 1.45)**</td><td align="char" char="." valign="bottom">0.199</td><td align="left" valign="bottom">0.39 (0.02, 8.74)**</td><td align="char" char="." valign="bottom">0.562</td><td align="char" char="." valign="bottom"><bold>1.96 (1.32, 2.91)**</bold></td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.68 (0.29, 1.6)**</td><td align="char" char="." valign="bottom">0.388</td></tr><tr><td align="char" char="." valign="bottom">286.3</td><td align="left" valign="bottom">Coagulation defects complicating pregnancy or postpartum</td><td align="char" char="." valign="bottom">2015</td><td align="char" char="." valign="bottom">10502418</td><td align="left" valign="bottom"><bold>1.15 (1.08, 1.22</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.02 (0.58, 1.79)</td><td align="char" char="." valign="bottom">0.946</td><td align="left" valign="bottom">1.14 (0.95, 1.38)</td><td align="char" char="." valign="bottom">0.164</td><td align="char" char="." valign="bottom"><bold>0.84 (0.79, 0.89</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom"><bold>0.88 (0.8, 0.97</bold>)</td><td align="char" char="." valign="bottom"><bold>0.013</bold></td></tr><tr><td align="char" char="." valign="bottom">286.7</td><td align="left" valign="bottom">Other and unspecified coagulation defects</td><td align="char" char="." valign="bottom">1085</td><td align="char" char="." valign="bottom">17621421</td><td align="left" valign="bottom"><bold>1.23 (1.05, 1.45</bold>)</td><td align="char" char="." valign="bottom"><bold>0.013</bold></td><td align="char" char="." valign="bottom">0.98 (0.45, 2.16)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom"><bold>1.52 (1.1, 2.08</bold>)</td><td align="char" char="." valign="bottom"><bold>0.011</bold></td><td align="char" char="." valign="bottom"><bold>0.74 (0.64, 0.85</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.03 (0.23, 4.72)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td colspan="14" style="author-callout-style-b8"><bold>Mental Disorders</bold></td></tr><tr><td align="char" char="." valign="bottom">300.1</td><td align="left" valign="bottom">Anxiety disorder</td><td align="char" char="." valign="bottom">7985</td><td align="char" char="." valign="bottom">17603188</td><td align="left" valign="bottom">1.03 (0.93, 1.14)</td><td align="char" char="." valign="bottom">0.575</td><td align="char" char="." valign="bottom">0.97 (0.8, 1.16)</td><td align="char" char="." valign="bottom">0.735</td><td align="left" valign="bottom">0.96 (0.66, 1.41)</td><td align="char" char="." valign="bottom">0.858</td><td align="char" char="." valign="bottom">0.99 (0.76, 1.29)</td><td align="char" char="." valign="bottom">0.953</td><td align="char" char="." valign="bottom"><bold>0.92 (0.86, 0.99</bold>)</td><td align="char" char="." valign="bottom"><bold>0.027</bold></td></tr><tr><td colspan="14" style="author-callout-style-b8"><bold>Neurological</bold></td></tr><tr><td align="char" char="." valign="bottom">333.8</td><td align="left" valign="bottom">Other degenerative diseases of the basal ganglia</td><td align="char" char="." valign="bottom">381</td><td align="char" char="." valign="bottom">17630209</td><td align="left" valign="bottom">0.78 (0.57, 1.07)</td><td align="char" char="." valign="bottom">0.128</td><td align="char" char="." valign="bottom">1.05 (0.11, 9.95)</td><td align="char" char="." valign="bottom">0.967</td><td align="left" valign="bottom">0.65 (0.24, 1.78)</td><td align="char" char="." valign="bottom">0.407</td><td align="char" char="." valign="bottom"><bold>1.32 (1.02, 1.71</bold>)</td><td align="char" char="." valign="bottom"><bold>0.033</bold></td><td align="char" char="." valign="bottom">1 (0.95, 1.05)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">339</td><td align="left" valign="bottom">Other headache syndromes</td><td align="char" char="." valign="bottom">3466</td><td align="char" char="." valign="bottom">17603269</td><td align="left" valign="bottom">1.05 (0.9, 1.22)</td><td align="char" char="." valign="bottom">0.546</td><td align="char" char="." valign="bottom">1.11 (0.95, 1.3)</td><td align="char" char="." valign="bottom">0.204</td><td align="left" valign="bottom">1.03 (0.39, 2.73)</td><td align="char" char="." valign="bottom">0.957</td><td align="char" char="." valign="bottom"><bold>0.9 (0.83, 0.99</bold>)</td><td align="char" char="." valign="bottom"><bold>0.023</bold></td><td align="char" char="." valign="bottom">1.06 (0.82, 1.36)</td><td align="char" char="." valign="bottom">0.688</td></tr><tr><td align="char" char="." valign="bottom">345</td><td align="left" valign="bottom">Epilepsy, recurrent seizures, convulsions</td><td align="char" char="." valign="bottom">23469</td><td align="char" char="." valign="bottom">17228780</td><td align="left" valign="bottom">0.99 (0.77, 1.28)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.96 (0.86, 1.08)</td><td align="char" char="." valign="bottom">0.51</td><td align="left" valign="bottom">0.97 (0.71, 1.32)</td><td align="char" char="." valign="bottom">0.853</td><td align="char" char="." valign="bottom">1.03 (0.96, 1.1)</td><td align="char" char="." valign="bottom">0.44</td><td align="char" char="." valign="bottom"><bold>0.94 (0.89, 1</bold>)</td><td align="char" char="." valign="bottom"><bold>0.039</bold></td></tr><tr><td align="char" char="." valign="bottom">345.3</td><td align="left" valign="bottom">Convulsions</td><td align="char" char="." valign="bottom">14391</td><td align="char" char="." valign="bottom">17351676</td><td align="left" valign="bottom">0.99 (0.76, 1.3)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.96 (0.79, 1.18)</td><td align="char" char="." valign="bottom">0.732</td><td align="left" valign="bottom">1 (0.88, 1.13)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">1.02 (0.89, 1.18)</td><td align="char" char="." valign="bottom">0.77</td><td align="char" char="." valign="bottom"><bold>0.92 (0.85, 0.99</bold>)</td><td align="char" char="." valign="bottom"><bold>0.036</bold></td></tr><tr><td colspan="14" style="author-callout-style-b8"><bold>Sense Organs</bold></td></tr><tr><td align="char" char="." valign="bottom">361.1</td><td align="left" valign="bottom">Retinal detachment with retinal defect</td><td align="char" char="." valign="bottom">3037</td><td align="char" char="." valign="bottom">17594394</td><td align="left" valign="bottom">1.06 (0.87, 1.29)</td><td align="char" char="." valign="bottom">0.582</td><td align="char" char="." valign="bottom">1.07 (0.69, 1.66)</td><td align="char" char="." valign="bottom">0.787</td><td align="left" valign="bottom">1.23 (0.9, 1.69)</td><td align="char" char="." valign="bottom">0.193</td><td align="char" char="." valign="bottom"><bold>0.88 (0.79, 0.98</bold>)</td><td align="char" char="." valign="bottom"><bold>0.022</bold></td><td align="char" char="." valign="bottom">0.97 (0.49, 1.96)</td><td align="char" char="." valign="bottom">0.948</td></tr><tr><td align="char" char="." valign="bottom">381</td><td align="left" valign="bottom">Otitis media and Eustachian tube disorders</td><td align="char" char="." valign="bottom">22790</td><td align="char" char="." valign="bottom">17144551</td><td align="left" valign="bottom"><bold>1.07 (1.03, 1.11</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.94 (0.86, 1.04)</td><td align="char" char="." valign="bottom">0.226</td><td align="left" valign="bottom">1.01 (0.55, 1.87)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom"><bold>0.95 (0.91, 1</bold>)</td><td align="char" char="." valign="bottom"><bold>0.039</bold></td><td align="char" char="." valign="bottom">0.96 (0.87, 1.06)</td><td align="char" char="." valign="bottom">0.437</td></tr><tr><td align="char" char="." valign="bottom">381.1</td><td align="left" valign="bottom">Otitis media</td><td align="char" char="." valign="bottom">12313</td><td align="char" char="." valign="bottom">17364091</td><td align="left" valign="bottom"><bold>1.09 (1.04, 1.14</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.95 (0.83, 1.09)</td><td align="char" char="." valign="bottom">0.449</td><td align="left" valign="bottom">0.98 (0.44, 2.22)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.94 (0.89, 1)</td><td align="char" char="." valign="bottom">0.067</td><td align="char" char="." valign="bottom">0.97 (0.82, 1.13)</td><td align="char" char="." valign="bottom">0.688</td></tr><tr><td align="char" char="." valign="bottom">381.2</td><td align="left" valign="bottom">Eustachian tube disorders</td><td align="char" char="." valign="bottom">2358</td><td align="char" char="." valign="bottom">17571118</td><td align="left" valign="bottom"><bold>1.15 (1.01, 1.31</bold>)</td><td align="char" char="." valign="bottom"><bold>0.033</bold></td><td align="char" char="." valign="bottom">0.9 (0.62, 1.29)</td><td align="char" char="." valign="bottom">0.566</td><td align="left" valign="bottom">0.87 (0.38, 2.01)</td><td align="char" char="." valign="bottom">0.765</td><td align="char" char="." valign="bottom">0.93 (0.74, 1.17)</td><td align="char" char="." valign="bottom">0.531</td><td align="char" char="." valign="bottom">0.88 (0.69, 1.13)</td><td align="char" char="." valign="bottom">0.32</td></tr><tr><td align="char" char="." valign="bottom">385.5</td><td align="left" valign="bottom">Tympanosclerosis and middle ear disease related to otitis media</td><td align="char" char="." valign="bottom">530</td><td align="char" char="." valign="bottom">17625215</td><td align="left" valign="bottom">1.25 (0.95, 1.64)</td><td align="char" char="." valign="bottom">0.114</td><td align="char" char="." valign="bottom">0.99 (0.55, 1.77)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom">1.21 (0.37, 3.96)</td><td align="char" char="." valign="bottom">0.761</td><td align="char" char="." valign="bottom"><bold>0.77 (0.6, 0.98</bold>)</td><td align="char" char="." valign="bottom"><bold>0.036</bold></td><td align="char" char="." valign="bottom">1.08 (0.29, 3.98)</td><td align="char" char="." valign="bottom">0.918</td></tr><tr><td align="char" char="." valign="bottom">386.9</td><td align="left" valign="bottom">Dizziness and giddiness (Light-headedness and vertigo)</td><td align="char" char="." valign="bottom">1060</td><td align="char" char="." valign="bottom">17624097</td><td align="left" valign="bottom"><bold>0.84 (0.73, 0.97</bold>)</td><td align="char" char="." valign="bottom"><bold>0.016</bold></td><td align="char" char="." valign="bottom">1.04 (0.43, 2.55)</td><td align="char" char="." valign="bottom">0.933</td><td align="left" valign="bottom">0.82 (0.42, 1.57)</td><td align="char" char="." valign="bottom">0.555</td><td align="char" char="." valign="bottom"><bold>1.2 (1.06, 1.37</bold>)</td><td align="char" char="." valign="bottom"><bold>0.005</bold></td><td align="char" char="." valign="bottom">1.08 (0.7, 1.68)</td><td align="char" char="." valign="bottom">0.738</td></tr><tr><td align="char" char="." valign="bottom">389</td><td align="left" valign="bottom">Hearing loss</td><td align="char" char="." valign="bottom">43238</td><td align="char" char="." valign="bottom">17166114</td><td align="left" valign="bottom">0.99 (0.88, 1.12)</td><td align="char" char="." valign="bottom">0.897</td><td align="char" char="." valign="bottom">1.01 (0.74, 1.37)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom">1.01 (0.78, 1.3)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">1.01 (0.83, 1.21)</td><td align="char" char="." valign="bottom">0.96</td><td align="char" char="." valign="bottom"><bold>1.06 (1.01, 1.1</bold>)</td><td align="char" char="." valign="bottom"><bold>0.009</bold></td></tr><tr><td align="char" char="." valign="bottom">389.3</td><td align="left" valign="bottom">Degenerative and vascular disorders of ear</td><td align="char" char="." valign="bottom">22354</td><td align="char" char="." valign="bottom">17419947</td><td align="left" valign="bottom">0.99 (0.81, 1.22)</td><td align="char" char="." valign="bottom">0.94</td><td align="char" char="." valign="bottom">1 (0.85, 1.19)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom">1.02 (0.53, 1.94)</td><td align="char" char="." valign="bottom">0.961</td><td align="char" char="." valign="bottom">1 (0.83, 1.22)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom"><bold>1.08 (1.02, 1.15</bold>)</td><td align="char" char="." valign="bottom"><bold>0.012</bold></td></tr><tr><td colspan="14" style="author-callout-style-b8"><bold>Circulatory System</bold></td></tr><tr><td align="char" char="." valign="bottom">394</td><td align="left" valign="bottom">Rheumatic disease of the heart valves</td><td align="char" char="." valign="bottom">8422</td><td align="char" char="." valign="bottom">17577658</td><td align="left" valign="bottom"><bold>1.08 (1.01, 1.16</bold>)</td><td align="char" char="." valign="bottom"><bold>0.029</bold></td><td align="char" char="." valign="bottom">0.98 (0.61, 1.57)</td><td align="char" char="." valign="bottom">0.924</td><td align="left" valign="bottom">0.93 (0.63, 1.38)</td><td align="char" char="." valign="bottom">0.744</td><td align="char" char="." valign="bottom">0.94 (0.86, 1.03)</td><td align="char" char="." valign="bottom">0.2</td><td align="char" char="." valign="bottom">0.96 (0.78, 1.19)</td><td align="char" char="." valign="bottom">0.729</td></tr><tr><td align="char" char="." valign="bottom">411.2</td><td align="left" valign="bottom">Myocardial infarction</td><td align="char" char="." valign="bottom">25905</td><td align="char" char="." valign="bottom">17411193</td><td align="left" valign="bottom">1.03 (0.96, 1.11)</td><td align="char" char="." valign="bottom">0.434</td><td align="char" char="." valign="bottom">1.06 (0.97, 1.16)</td><td align="char" char="." valign="bottom">0.188</td><td align="left" valign="bottom">1.03 (0.58, 1.8)</td><td align="char" char="." valign="bottom">0.932</td><td align="char" char="." valign="bottom"><bold>0.94 (0.9, 0.98</bold>)</td><td align="char" char="." valign="bottom"><bold>0.008</bold></td><td align="char" char="." valign="bottom">1.02 (0.83, 1.26)</td><td align="char" char="." valign="bottom">0.867</td></tr><tr><td align="char" char="." valign="bottom">415</td><td align="left" valign="bottom">Pulmonary heart disease</td><td align="char" char="." valign="bottom">10870</td><td align="char" char="." valign="bottom">17565369</td><td align="left" valign="bottom"><bold>1.2 (1.15, 1.26</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.07 (0.9, 1.27)</td><td align="char" char="." valign="bottom">0.475</td><td align="left" valign="bottom">1.14 (0.96, 1.36)</td><td align="char" char="." valign="bottom">0.125</td><td align="char" char="." valign="bottom"><bold>0.78 (0.75, 0.82</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.95 (0.82, 1.09)</td><td align="char" char="." valign="bottom">0.482</td></tr><tr><td align="char" char="." valign="bottom">415.11</td><td align="left" valign="bottom">Pulmonary embolism and infarction, acute</td><td align="char" char="." valign="bottom">1533</td><td align="char" char="." valign="bottom">17612465</td><td align="left" valign="bottom"><bold>1.39 (1.21, 1.59</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.11 (0.56, 2.18)</td><td align="char" char="." valign="bottom">0.781</td><td align="left" valign="bottom">1.14 (0.44, 2.98)</td><td align="char" char="." valign="bottom">0.798</td><td align="char" char="." valign="bottom"><bold>0.65 (0.57, 0.75</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.88 (0.59, 1.32)</td><td align="char" char="." valign="bottom">0.562</td></tr><tr><td align="char" char="." valign="bottom">425.12</td><td align="left" valign="bottom">Other hypertrophic cardiomyopathy</td><td align="char" char="." valign="bottom">466</td><td align="char" char="." valign="bottom">17628820</td><td align="left" valign="bottom">0.81 (0.61, 1.07)</td><td align="char" char="." valign="bottom">0.138</td><td align="char" char="." valign="bottom">0.83 (0.35, 1.98)</td><td align="char" char="." valign="bottom">0.683</td><td align="left" valign="bottom">1.11 (0.12, 10.23)</td><td align="char" char="." valign="bottom">0.93</td><td align="char" char="." valign="bottom"><bold>1.3 (1.03, 1.64</bold>)</td><td align="char" char="." valign="bottom"><bold>0.028</bold></td><td align="char" char="." valign="bottom">0.91 (0.32, 2.6)</td><td align="char" char="." valign="bottom">0.877</td></tr><tr><td align="char" char="." valign="bottom">428.1</td><td align="left" valign="bottom">Congestive heart failure (CHF) NOS</td><td align="char" char="." valign="bottom">8357</td><td align="char" char="." valign="bottom">17595328</td><td align="left" valign="bottom">1.03 (0.94, 1.13)</td><td align="char" char="." valign="bottom">0.5</td><td align="char" char="." valign="bottom">1.02 (0.76, 1.37)</td><td align="char" char="." valign="bottom">0.906</td><td align="left" valign="bottom">1.12 (0.96, 1.3)</td><td align="char" char="." valign="bottom">0.14</td><td align="char" char="." valign="bottom"><bold>0.94 (0.89, 0.99</bold>)</td><td align="char" char="." valign="bottom"><bold>0.028</bold></td><td align="char" char="." valign="bottom">1.01 (0.7, 1.46)</td><td align="char" char="." valign="bottom">0.961</td></tr><tr><td align="char" char="." valign="bottom">440</td><td align="left" valign="bottom">Atherosclerosis</td><td align="char" char="." valign="bottom">10901</td><td align="char" char="." valign="bottom">17554704</td><td align="left" valign="bottom">1.05 (0.95, 1.16)</td><td align="char" char="." valign="bottom">0.345</td><td align="char" char="." valign="bottom">1.1 (0.96, 1.25)</td><td align="char" char="." valign="bottom">0.169</td><td align="left" valign="bottom">1.12 (0.91, 1.37)</td><td align="char" char="." valign="bottom">0.3</td><td align="char" char="." valign="bottom"><bold>0.9 (0.85, 0.95</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.04 (0.88, 1.23)</td><td align="char" char="." valign="bottom">0.675</td></tr><tr><td align="char" char="." valign="bottom">440.2</td><td align="left" valign="bottom">Atherosclerosis of the extremities</td><td align="char" char="." valign="bottom">8348</td><td align="char" char="." valign="bottom">17570336</td><td align="left" valign="bottom">1.06 (0.96, 1.18)</td><td align="char" char="." valign="bottom">0.258</td><td align="char" char="." valign="bottom">1.09 (0.9, 1.32)</td><td align="char" char="." valign="bottom">0.406</td><td align="left" valign="bottom">1.08 (0.75, 1.55)</td><td align="char" char="." valign="bottom">0.686</td><td align="char" char="." valign="bottom"><bold>0.9 (0.84, 0.96</bold>)</td><td align="char" char="." valign="bottom"><bold>0.002</bold></td><td align="char" char="." valign="bottom">1.03 (0.8, 1.33)</td><td align="char" char="." valign="bottom">0.823</td></tr><tr><td align="char" char="." valign="bottom">442.2</td><td align="left" valign="bottom">Aneurysm of iliac artery</td><td align="char" char="." valign="bottom">326</td><td align="char" char="." valign="bottom">17630660</td><td align="left" valign="bottom"><bold>0.75 (0.64, 0.89</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.13 (0.63, 2.04)</td><td align="char" char="." valign="bottom">0.69</td><td align="left" valign="bottom">1.2 (0.61, 2.38)</td><td align="char" char="." valign="bottom">0.607</td><td align="char" char="." valign="bottom"><bold>1.21 (1, 1.47</bold>)</td><td align="char" char="." valign="bottom"><bold>0.045</bold></td><td align="char" char="." valign="bottom"><bold>0.72 (0.6, 0.87</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="char" char="." valign="bottom">443</td><td align="left" valign="bottom">Peripheral vascular disease</td><td align="char" char="." valign="bottom">13791</td><td align="char" char="." valign="bottom">17546796</td><td align="left" valign="bottom">1.05 (0.98, 1.12)</td><td align="char" char="." valign="bottom">0.153</td><td align="char" char="." valign="bottom">1.01 (0.59, 1.73)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom">1.03 (0.71, 1.5)</td><td align="char" char="." valign="bottom">0.872</td><td align="char" char="." valign="bottom"><bold>0.94 (0.89, 1</bold>)</td><td align="char" char="." valign="bottom"><bold>0.035</bold></td><td align="char" char="." valign="bottom">1.03 (0.91, 1.18)</td><td align="char" char="." valign="bottom">0.63</td></tr><tr><td align="char" char="." valign="bottom">443.7</td><td align="left" valign="bottom">Peripheral angiopathy in diseases classified elsewhere</td><td align="char" char="." valign="bottom">3677</td><td align="char" char="." valign="bottom">17611414</td><td align="left" valign="bottom">1.02 (0.68, 1.51)</td><td align="char" char="." valign="bottom">0.94</td><td align="char" char="." valign="bottom">1.1 (0.9, 1.34)</td><td align="char" char="." valign="bottom">0.37</td><td align="left" valign="bottom">1.1 (0.78, 1.55)</td><td align="char" char="." valign="bottom">0.603</td><td align="char" char="." valign="bottom">0.93 (0.83, 1.04)</td><td align="char" char="." valign="bottom">0.214</td><td align="char" char="." valign="bottom"><bold>1.18 (1.05, 1.31</bold>)</td><td align="char" char="." valign="bottom"><bold>0.004</bold></td></tr><tr><td align="char" char="." valign="bottom">444</td><td align="left" valign="bottom">Arterial embolism and thrombosis</td><td align="char" char="." valign="bottom">2390</td><td align="char" char="." valign="bottom">17614619</td><td align="left" valign="bottom">1.14 (0.98, 1.34)</td><td align="char" char="." valign="bottom">0.093</td><td align="char" char="." valign="bottom">1.11 (0.77, 1.61)</td><td align="char" char="." valign="bottom">0.583</td><td align="left" valign="bottom">1.28 (0.93, 1.76)</td><td align="char" char="." valign="bottom">0.134</td><td align="char" char="." valign="bottom"><bold>0.79 (0.7, 0.89</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1 (0.92, 1.08)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">444.1</td><td align="left" valign="bottom">Arterial embolism and thrombosis of lower extremity artery</td><td align="char" char="." valign="bottom">1286</td><td align="char" char="." valign="bottom">17623872</td><td align="left" valign="bottom">1.13 (0.78, 1.63)</td><td align="char" char="." valign="bottom">0.533</td><td align="char" char="." valign="bottom">1.13 (0.61, 2.13)</td><td align="char" char="." valign="bottom">0.706</td><td align="left" valign="bottom">1.38 (0.86, 2.23)</td><td align="char" char="." valign="bottom">0.185</td><td align="char" char="." valign="bottom"><bold>0.78 (0.63, 0.97</bold>)</td><td align="char" char="." valign="bottom"><bold>0.022</bold></td><td align="char" char="." valign="bottom">0.98 (0.35, 2.76)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">451</td><td align="left" valign="bottom">Phlebitis and thrombophlebitis</td><td align="char" char="." valign="bottom">16748</td><td align="char" char="." valign="bottom">17479709</td><td align="left" valign="bottom"><bold>1.22 (1.18, 1.25</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom"><bold>1.15 (1.09, 1.21</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom"><bold>1.29 (1.18, 1.4</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom"><bold>0.73 (0.7, 0.75</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.97 (0.84, 1.13)</td><td align="char" char="." valign="bottom">0.717</td></tr><tr><td align="char" char="." valign="bottom">451.2</td><td align="left" valign="bottom">Phlebitis and thrombophlebitis of lower extremities</td><td align="char" char="." valign="bottom">15650</td><td align="char" char="." valign="bottom">17489528</td><td align="left" valign="bottom"><bold>1.23 (1.19, 1.27</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom"><bold>1.14 (1.08, 1.2</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom"><bold>1.31 (1.2, 1.42</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom"><bold>0.72 (0.69, 0.74</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.97 (0.84, 1.12)</td><td align="char" char="." valign="bottom">0.678</td></tr><tr><td align="char" char="." valign="bottom">452</td><td align="left" valign="bottom">Other venous embolism and thrombosis</td><td align="char" char="." valign="bottom">4275</td><td align="char" char="." valign="bottom">17607194</td><td align="left" valign="bottom"><bold>1.24 (1.16, 1.32</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom"><bold>1.21 (1.07, 1.36</bold>)</td><td align="char" char="." valign="bottom"><bold>0.002</bold></td><td align="left" valign="bottom"><bold>1.31 (1.1, 1.56</bold>)</td><td align="char" char="." valign="bottom"><bold>0.003</bold></td><td align="char" char="." valign="bottom"><bold>0.69 (0.64, 0.74</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1 (0.89, 1.11)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">452.8</td><td align="left" valign="bottom">Postphlebitic syndrome</td><td align="char" char="." valign="bottom">341</td><td align="char" char="." valign="bottom">17629425</td><td align="left" valign="bottom"><bold>1.35 (1.08, 1.68</bold>)</td><td align="char" char="." valign="bottom"><bold>0.009</bold></td><td align="char" char="." valign="bottom">1.26 (0.76, 2.08)</td><td align="char" char="." valign="bottom">0.378</td><td align="left" valign="bottom"><bold>1.82 (1.13, 2.94</bold>)</td><td align="char" char="." valign="bottom"><bold>0.014</bold></td><td align="char" char="." valign="bottom"><bold>0.55 (0.45, 0.67</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.18 (0.54, 2.56)</td><td align="char" char="." valign="bottom">0.688</td></tr><tr><td align="char" char="." valign="bottom">454</td><td align="left" valign="bottom">Varicose veins</td><td align="char" char="." valign="bottom">16500</td><td align="char" char="." valign="bottom">17381971</td><td align="left" valign="bottom"><bold>1.1 (1.01, 1.2</bold>)</td><td align="char" char="." valign="bottom"><bold>0.032</bold></td><td align="char" char="." valign="bottom">0.98 (0.57, 1.68)</td><td align="char" char="." valign="bottom">0.946</td><td align="left" valign="bottom">1.04 (0.51, 2.1)</td><td align="char" char="." valign="bottom">0.93</td><td align="char" char="." valign="bottom">0.91 (0.83, 1)</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">0.98 (0.67, 1.42)</td><td align="char" char="." valign="bottom">0.906</td></tr><tr><td align="char" char="." valign="bottom">455</td><td align="left" valign="bottom">Hemorrhoids</td><td align="char" char="." valign="bottom">9001</td><td align="char" char="." valign="bottom">17523962</td><td align="left" valign="bottom">0.95 (0.84, 1.08)</td><td align="char" char="." valign="bottom">0.481</td><td align="char" char="." valign="bottom">0.91 (0.78, 1.08)</td><td align="char" char="." valign="bottom">0.279</td><td align="left" valign="bottom">0.91 (0.67, 1.24)</td><td align="char" char="." valign="bottom">0.562</td><td align="char" char="." valign="bottom"><bold>1.1 (1.03, 1.18</bold>)</td><td align="char" char="." valign="bottom"><bold>0.005</bold></td><td align="char" char="." valign="bottom">0.99 (0.67, 1.46)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">456</td><td align="left" valign="bottom">Chronic venous insufficiency [CVI]</td><td align="char" char="." valign="bottom">925</td><td align="char" char="." valign="bottom">17626709</td><td align="left" valign="bottom"><bold>1.24 (1.07, 1.44</bold>)</td><td align="char" char="." valign="bottom"><bold>0.004</bold></td><td align="char" char="." valign="bottom">1.04 (0.23, 4.7)</td><td align="char" char="." valign="bottom">0.967</td><td align="left" valign="bottom">1.37 (0.91, 2.05)</td><td align="char" char="." valign="bottom">0.131</td><td align="char" char="." valign="bottom"><bold>0.73 (0.64, 0.83</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.94 (0.49, 1.79)</td><td align="char" char="." valign="bottom">0.858</td></tr><tr><td align="char" char="." valign="bottom">459</td><td align="left" valign="bottom">Other disorders of circulatory system</td><td align="char" char="." valign="bottom">2555</td><td align="char" char="." valign="bottom">17616713</td><td align="left" valign="bottom">1.12 (0.99, 1.27)</td><td align="char" char="." valign="bottom">0.076</td><td align="char" char="." valign="bottom">1.12 (0.85, 1.48)</td><td align="char" char="." valign="bottom">0.433</td><td align="left" valign="bottom">1.15 (0.75, 1.75)</td><td align="char" char="." valign="bottom">0.528</td><td align="char" char="." valign="bottom"><bold>0.82 (0.75, 0.9</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.08 (0.8, 1.46)</td><td align="char" char="." valign="bottom">0.636</td></tr><tr><td align="char" char="." valign="bottom">459.9</td><td align="left" valign="bottom">Circulatory disease NEC</td><td align="char" char="." valign="bottom">2174</td><td align="char" char="." valign="bottom">17618930</td><td align="left" valign="bottom"><bold>1.16 (1.02, 1.31</bold>)</td><td align="char" char="." valign="bottom"><bold>0.024</bold></td><td align="char" char="." valign="bottom">1.13 (0.86, 1.5)</td><td align="char" char="." valign="bottom">0.381</td><td align="left" valign="bottom">1.22 (0.85, 1.74)</td><td align="char" char="." valign="bottom">0.279</td><td align="char" char="." valign="bottom"><bold>0.78 (0.71, 0.86</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.02 (0.38, 2.74)</td><td align="char" char="." valign="bottom">0.966</td></tr><tr><td colspan="14" style="author-callout-style-b8"><bold>Respiratory</bold></td></tr><tr><td align="char" char="." valign="bottom">474</td><td align="left" valign="bottom">Acute and chronic tonsillitis</td><td align="char" char="." valign="bottom">41427</td><td align="char" char="." valign="bottom">16817602</td><td align="left" valign="bottom"><bold>1.1 (1.08, 1.13</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom"><bold>0.93 (0.88, 0.97</bold>)</td><td align="char" char="." valign="bottom"><bold>0.002</bold></td><td align="left" valign="bottom">1.01 (0.63, 1.63)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom"><bold>0.94 (0.91, 0.96</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.97 (0.9, 1.05)</td><td align="char" char="." valign="bottom">0.466</td></tr><tr><td align="char" char="." valign="bottom">474.2</td><td align="left" valign="bottom">Chronic tonsillitis and adenoiditis</td><td align="char" char="." valign="bottom">27077</td><td align="char" char="." valign="bottom">17030480</td><td align="left" valign="bottom"><bold>1.14 (1.11, 1.17</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom"><bold>0.89 (0.84, 0.93</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">1.02 (0.75, 1.4)</td><td align="char" char="." valign="bottom">0.897</td><td align="char" char="." valign="bottom"><bold>0.92 (0.89, 0.94</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.96 (0.89, 1.03)</td><td align="char" char="." valign="bottom">0.259</td></tr><tr><td align="char" char="." valign="bottom">477</td><td align="left" valign="bottom">Epistaxis or throat hemorrhage</td><td align="char" char="." valign="bottom">12337</td><td align="char" char="." valign="bottom">17506794</td><td align="left" valign="bottom"><bold>0.93 (0.89, 0.98</bold>)</td><td align="char" char="." valign="bottom"><bold>0.006</bold></td><td align="char" char="." valign="bottom">0.92 (0.83, 1.02)</td><td align="char" char="." valign="bottom">0.118</td><td align="left" valign="bottom">0.94 (0.71, 1.23)</td><td align="char" char="." valign="bottom">0.648</td><td align="char" char="." valign="bottom"><bold>1.12 (1.08, 1.16</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.01 (0.73, 1.41)</td><td align="char" char="." valign="bottom">0.948</td></tr><tr><td align="char" char="." valign="bottom">495</td><td align="left" valign="bottom">Asthma</td><td align="char" char="." valign="bottom">31106</td><td align="char" char="." valign="bottom">17238738</td><td align="left" valign="bottom"><bold>1.04 (1, 1.08</bold>)</td><td align="char" char="." valign="bottom"><bold>0.028</bold></td><td align="char" char="." valign="bottom"><bold>0.94 (0.88, 0.99</bold>)</td><td align="char" char="." valign="bottom"><bold>0.023</bold></td><td align="left" valign="bottom">1 (1, 1)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.99 (0.9, 1.08)</td><td align="char" char="." valign="bottom">0.777</td><td align="char" char="." valign="bottom">0.99 (0.78, 1.27)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td colspan="14" style="author-callout-style-b8"><bold>Digestive</bold></td></tr><tr><td align="char" char="." valign="bottom">530.11</td><td align="left" valign="bottom">GERD</td><td align="char" char="." valign="bottom">7461</td><td align="char" char="." valign="bottom">17582158</td><td align="left" valign="bottom">0.99 (0.69, 1.43)</td><td align="char" char="." valign="bottom">0.966</td><td align="char" char="." valign="bottom"><bold>1.12 (1.03, 1.22</bold>)</td><td align="char" char="." valign="bottom"><bold>0.007</bold></td><td align="left" valign="bottom">1.04 (0.62, 1.72)</td><td align="char" char="." valign="bottom">0.897</td><td align="char" char="." valign="bottom">0.95 (0.88, 1.03)</td><td align="char" char="." valign="bottom">0.223</td><td align="char" char="." valign="bottom"><bold>1.12 (1.03, 1.21</bold>)</td><td align="char" char="." valign="bottom"><bold>0.007</bold></td></tr><tr><td align="char" char="." valign="bottom">530.7</td><td align="left" valign="bottom">Gastroesophageal laceration-hemorrhage syndrome</td><td align="char" char="." valign="bottom">597</td><td align="char" char="." valign="bottom">17623900</td><td align="left" valign="bottom">1.16 (0.8, 1.66)</td><td align="char" char="." valign="bottom">0.439</td><td align="char" char="." valign="bottom">1.04 (0.15, 7.23)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom"><bold>0.43 (0.22, 0.83</bold>)</td><td align="char" char="." valign="bottom"><bold>0.012</bold></td><td align="char" char="." valign="bottom">0.94 (0.44, 2.02)</td><td align="char" char="." valign="bottom">0.883</td><td align="char" char="." valign="bottom">1.09 (0.39, 2.99)</td><td align="char" char="." valign="bottom">0.883</td></tr><tr><td align="char" char="." valign="bottom">531</td><td align="left" valign="bottom">Peptic ulcer (excl. esophageal)</td><td align="char" char="." valign="bottom">16678</td><td align="char" char="." valign="bottom">17443704</td><td align="left" valign="bottom"><bold>0.9 (0.87, 0.94</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1 (0.94, 1.07)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom">0.92 (0.75, 1.14)</td><td align="char" char="." valign="bottom">0.471</td><td align="char" char="." valign="bottom"><bold>1.12 (1.08, 1.16</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.02 (0.83, 1.25)</td><td align="char" char="." valign="bottom">0.86</td></tr><tr><td align="char" char="." valign="bottom">531.1</td><td align="left" valign="bottom">Hemorrhage from gastrointestinal ulcer</td><td align="char" char="." valign="bottom">6277</td><td align="char" char="." valign="bottom">17583751</td><td align="left" valign="bottom"><bold>0.91 (0.84, 0.98</bold>)</td><td align="char" char="." valign="bottom"><bold>0.009</bold></td><td align="char" char="." valign="bottom">0.89 (0.75, 1.04)</td><td align="char" char="." valign="bottom">0.149</td><td align="left" valign="bottom">0.91 (0.6, 1.4)</td><td align="char" char="." valign="bottom">0.688</td><td align="char" char="." valign="bottom"><bold>1.17 (1.11, 1.25</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.07 (0.91, 1.27)</td><td align="char" char="." valign="bottom">0.421</td></tr><tr><td align="char" char="." valign="bottom">531.2</td><td align="left" valign="bottom">Gastric ulcer</td><td align="char" char="." valign="bottom">6745</td><td align="char" char="." valign="bottom">17555312</td><td align="left" valign="bottom"><bold>0.91 (0.85, 0.98</bold>)</td><td align="char" char="." valign="bottom"><bold>0.008</bold></td><td align="char" char="." valign="bottom">1.01 (0.63, 1.63)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom">0.92 (0.62, 1.36)</td><td align="char" char="." valign="bottom">0.681</td><td align="char" char="." valign="bottom"><bold>1.11 (1.04, 1.18</bold>)</td><td align="char" char="." valign="bottom"><bold>0.002</bold></td><td align="char" char="." valign="bottom">0.97 (0.73, 1.28)</td><td align="char" char="." valign="bottom">0.838</td></tr><tr><td align="char" char="." valign="bottom">531.3</td><td align="left" valign="bottom">Duodenal ulcer</td><td align="char" char="." valign="bottom">4534</td><td align="char" char="." valign="bottom">17555684</td><td align="left" valign="bottom"><bold>0.88 (0.8, 0.96</bold>)</td><td align="char" char="." valign="bottom"><bold>0.007</bold></td><td align="char" char="." valign="bottom">1.06 (0.71, 1.57)</td><td align="char" char="." valign="bottom">0.803</td><td align="left" valign="bottom">0.97 (0.21, 4.56)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom"><bold>1.12 (1.01, 1.24</bold>)</td><td align="char" char="." valign="bottom"><bold>0.028</bold></td><td align="char" char="." valign="bottom">1.05 (0.77, 1.43)</td><td align="char" char="." valign="bottom">0.789</td></tr><tr><td align="char" char="." valign="bottom">531.5</td><td align="left" valign="bottom">Gastrojejunal ulcer</td><td align="char" char="." valign="bottom">586</td><td align="char" char="." valign="bottom">17628539</td><td align="left" valign="bottom">0.83 (0.61, 1.11)</td><td align="char" char="." valign="bottom">0.213</td><td align="char" char="." valign="bottom"><bold>1.41 (1.08, 1.84</bold>)</td><td align="char" char="." valign="bottom"><bold>0.012</bold></td><td align="left" valign="bottom">1.12 (0.23, 5.41)</td><td align="char" char="." valign="bottom">0.897</td><td align="char" char="." valign="bottom">1.01 (0.64, 1.6)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.85 (0.56, 1.28)</td><td align="char" char="." valign="bottom">0.439</td></tr><tr><td align="char" char="." valign="bottom">550</td><td align="left" valign="bottom">Abdominal hernia</td><td align="char" char="." valign="bottom">47761</td><td align="char" char="." valign="bottom">16976073</td><td align="left" valign="bottom">1.01 (0.94, 1.09)</td><td align="char" char="." valign="bottom">0.757</td><td align="char" char="." valign="bottom"><bold>0.94 (0.89, 0.99</bold>)</td><td align="char" char="." valign="bottom"><bold>0.021</bold></td><td align="left" valign="bottom">0.97 (0.81, 1.17)</td><td align="char" char="." valign="bottom">0.765</td><td align="char" char="." valign="bottom">1.02 (0.96, 1.08)</td><td align="char" char="." valign="bottom">0.575</td><td align="char" char="." valign="bottom">1.01 (0.77, 1.32)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">562</td><td align="left" valign="bottom">Diverticulosis and diverticulitis</td><td align="char" char="." valign="bottom">16569</td><td align="char" char="." valign="bottom">17515568</td><td align="left" valign="bottom">0.94 (0.87, 1.03)</td><td align="char" char="." valign="bottom">0.19</td><td align="char" char="." valign="bottom">0.92 (0.82, 1.03)</td><td align="char" char="." valign="bottom">0.138</td><td align="left" valign="bottom">0.91 (0.7, 1.18)</td><td align="char" char="." valign="bottom">0.481</td><td align="char" char="." valign="bottom"><bold>1.11 (1.06, 1.17</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.98 (0.75, 1.28)</td><td align="char" char="." valign="bottom">0.884</td></tr><tr><td align="char" char="." valign="bottom">562.1</td><td align="left" valign="bottom">Diverticulosis</td><td align="char" char="." valign="bottom">16569</td><td align="char" char="." valign="bottom">17515568</td><td align="left" valign="bottom">0.94 (0.87, 1.03)</td><td align="char" char="." valign="bottom">0.19</td><td align="char" char="." valign="bottom">0.92 (0.82, 1.03)</td><td align="char" char="." valign="bottom">0.138</td><td align="left" valign="bottom">0.91 (0.7, 1.18)</td><td align="char" char="." valign="bottom">0.481</td><td align="char" char="." valign="bottom"><bold>1.11 (1.06, 1.17</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.98 (0.75, 1.28)</td><td align="char" char="." valign="bottom">0.884</td></tr><tr><td align="char" char="." valign="bottom">571.81</td><td align="left" valign="bottom">Portal hypertension</td><td align="char" char="." valign="bottom">1101</td><td align="char" char="." valign="bottom">17627608</td><td align="left" valign="bottom">0.94 (0.66, 1.35)</td><td align="char" char="." valign="bottom">0.766</td><td align="char" char="." valign="bottom">1.17 (0.83, 1.63)</td><td align="char" char="." valign="bottom">0.376</td><td align="left" valign="bottom"><bold>0.62 (0.43, 0.9</bold>)</td><td align="char" char="." valign="bottom"><bold>0.011</bold></td><td align="char" char="." valign="bottom">1.06 (0.76, 1.47)</td><td align="char" char="." valign="bottom">0.746</td><td align="char" char="." valign="bottom">0.99 (0.52, 1.88)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">574</td><td align="left" valign="bottom">Cholelithiasis and cholecystitis</td><td align="char" char="." valign="bottom">31530</td><td align="char" char="." valign="bottom">17299206</td><td align="left" valign="bottom"><bold>1.05 (1.02, 1.09</bold>)</td><td align="char" char="." valign="bottom"><bold>0.004</bold></td><td align="char" char="." valign="bottom">0.98 (0.85, 1.13)</td><td align="char" char="." valign="bottom">0.766</td><td align="left" valign="bottom">0.99 (0.64, 1.53)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.96 (0.92, 1)</td><td align="char" char="." valign="bottom">0.062</td><td align="char" char="." valign="bottom">1.01 (0.73, 1.39)</td><td align="char" char="." valign="bottom">0.957</td></tr><tr><td align="char" char="." valign="bottom">574.1</td><td align="left" valign="bottom">Cholelithiasis</td><td align="char" char="." valign="bottom">24028</td><td align="char" char="." valign="bottom">17364917</td><td align="left" valign="bottom"><bold>1.05 (1.01, 1.1</bold>)</td><td align="char" char="." valign="bottom"><bold>0.029</bold></td><td align="char" char="." valign="bottom">0.98 (0.81, 1.18)</td><td align="char" char="." valign="bottom">0.809</td><td align="left" valign="bottom">0.99 (0.49, 1.96)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.96 (0.91, 1.02)</td><td align="char" char="." valign="bottom">0.183</td><td align="char" char="." valign="bottom">1.01 (0.75, 1.35)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">574.12</td><td align="left" valign="bottom">Cholelithiasis with other cholecystitis</td><td align="char" char="." valign="bottom">2650</td><td align="char" char="." valign="bottom">17605642</td><td align="left" valign="bottom"><bold>1.12 (1, 1.25</bold>)</td><td align="char" char="." valign="bottom"><bold>0.044</bold></td><td align="char" char="." valign="bottom">0.88 (0.69, 1.12)</td><td align="char" char="." valign="bottom">0.32</td><td align="left" valign="bottom">0.91 (0.48, 1.7)</td><td align="char" char="." valign="bottom">0.77</td><td align="char" char="." valign="bottom">0.95 (0.76, 1.2)</td><td align="char" char="." valign="bottom">0.688</td><td align="char" char="." valign="bottom">0.96 (0.61, 1.52)</td><td align="char" char="." valign="bottom">0.878</td></tr><tr><td align="char" char="." valign="bottom">574.2</td><td align="left" valign="bottom">Calculus of bile duct</td><td align="char" char="." valign="bottom">8401</td><td align="char" char="." valign="bottom">17560937</td><td align="left" valign="bottom"><bold>1.07 (1, 1.15</bold>)</td><td align="char" char="." valign="bottom"><bold>0.042</bold></td><td align="char" char="." valign="bottom">0.95 (0.78, 1.17)</td><td align="char" char="." valign="bottom">0.651</td><td align="left" valign="bottom">0.98 (0.46, 2.06)</td><td align="char" char="." valign="bottom">0.953</td><td align="char" char="." valign="bottom">0.95 (0.87, 1.05)</td><td align="char" char="." valign="bottom">0.33</td><td align="char" char="." valign="bottom">1.07 (0.94, 1.21)</td><td align="char" char="." valign="bottom">0.32</td></tr><tr><td align="char" char="." valign="bottom">575.2</td><td align="left" valign="bottom">Obstruction of bile duct</td><td align="char" char="." valign="bottom">1593</td><td align="char" char="." valign="bottom">17626684</td><td align="left" valign="bottom"><bold>1.24 (1.1, 1.41</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.97 (0.28, 3.43)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom">1.04 (0.18, 5.91)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom"><bold>0.8 (0.7, 0.91</bold>)</td><td align="char" char="." valign="bottom"><bold>0.001</bold></td><td align="char" char="." valign="bottom">1.1 (0.71, 1.69)</td><td align="char" char="." valign="bottom">0.688</td></tr><tr><td align="char" char="." valign="bottom">578</td><td align="left" valign="bottom">Gastrointestinal hemorrhage</td><td align="char" char="." valign="bottom">20111</td><td align="char" char="." valign="bottom">17502200</td><td align="left" valign="bottom">0.96 (0.9, 1.03)</td><td align="char" char="." valign="bottom">0.296</td><td align="char" char="." valign="bottom">0.94 (0.83, 1.08)</td><td align="char" char="." valign="bottom">0.393</td><td align="left" valign="bottom">0.91 (0.78, 1.07)</td><td align="char" char="." valign="bottom">0.249</td><td align="char" char="." valign="bottom"><bold>1.08 (1.03, 1.12</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.01 (0.77, 1.33)</td><td align="char" char="." valign="bottom">0.93</td></tr><tr><td align="char" char="." valign="bottom">578.8</td><td align="left" valign="bottom">Hemorrhage of rectum and anus</td><td align="char" char="." valign="bottom">11095</td><td align="char" char="." valign="bottom">17555331</td><td align="left" valign="bottom">0.96 (0.87, 1.06)</td><td align="char" char="." valign="bottom">0.413</td><td align="char" char="." valign="bottom">0.93 (0.79, 1.1)</td><td align="char" char="." valign="bottom">0.395</td><td align="left" valign="bottom">0.92 (0.71, 1.18)</td><td align="char" char="." valign="bottom">0.505</td><td align="char" char="." valign="bottom"><bold>1.09 (1.03, 1.15</bold>)</td><td align="char" char="." valign="bottom"><bold>0.004</bold></td><td align="char" char="." valign="bottom">1 (0.8, 1.26)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td colspan="14" style="author-callout-style-b8"><bold>Genitourinary</bold></td></tr><tr><td align="char" char="." valign="bottom">614.51</td><td align="left" valign="bottom">Cervicitis and endocervicitis</td><td align="char" char="." valign="bottom">660</td><td align="char" char="." valign="bottom">10488791</td><td align="left" valign="bottom">0.97 (0.52, 1.8)</td><td align="char" char="." valign="bottom">0.918</td><td align="char" char="." valign="bottom">1.1 (0.7, 1.73)</td><td align="char" char="." valign="bottom">0.696</td><td align="left" valign="bottom"><bold>1.4 (1.03, 1.91</bold>)</td><td align="char" char="." valign="bottom"><bold>0.033</bold></td><td align="char" char="." valign="bottom">0.93 (0.64, 1.34)</td><td align="char" char="." valign="bottom">0.706</td><td align="char" char="." valign="bottom">1.16 (0.86, 1.57)</td><td align="char" char="." valign="bottom">0.326</td></tr><tr><td align="char" char="." valign="bottom">622.2</td><td align="left" valign="bottom">Mucous polyp of cervix</td><td align="char" char="." valign="bottom">1401</td><td align="char" char="." valign="bottom">10498802</td><td align="left" valign="bottom"><bold>1.17 (1.03, 1.34</bold>)</td><td align="char" char="." valign="bottom"><bold>0.02</bold></td><td align="char" char="." valign="bottom">0.99 (0.64, 1.53)</td><td align="char" char="." valign="bottom">0.97</td><td align="left" valign="bottom">1.12 (0.56, 2.21)</td><td align="char" char="." valign="bottom">0.766</td><td align="char" char="." valign="bottom"><bold>0.83 (0.73, 0.95</bold>)</td><td align="char" char="." valign="bottom"><bold>0.007</bold></td><td align="char" char="." valign="bottom">0.97 (0.43, 2.18)</td><td align="char" char="." valign="bottom">0.948</td></tr><tr><td align="char" char="." valign="bottom">626.12</td><td align="left" valign="bottom">Excessive or frequent menstruation</td><td align="char" char="." valign="bottom">10504</td><td align="char" char="." valign="bottom">10375823</td><td align="left" valign="bottom"><bold>0.92 (0.86, 0.99</bold>)</td><td align="char" char="." valign="bottom"><bold>0.026</bold></td><td align="char" char="." valign="bottom">0.96 (0.74, 1.24)</td><td align="char" char="." valign="bottom">0.757</td><td align="left" valign="bottom">1.02 (0.48, 2.14)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom"><bold>1.1 (1.03, 1.17</bold>)</td><td align="char" char="." valign="bottom"><bold>0.004</bold></td><td align="char" char="." valign="bottom">0.97 (0.76, 1.23)</td><td align="char" char="." valign="bottom">0.811</td></tr><tr><td colspan="14" style="author-callout-style-b8"><bold>Pregnancy Complications</bold></td></tr><tr><td align="char" char="." valign="bottom">634.3</td><td align="left" valign="bottom">Ectopic pregnancy</td><td align="char" char="." valign="bottom">5034</td><td align="char" char="." valign="bottom">10426967</td><td align="left" valign="bottom">0.97 (0.87, 1.08)</td><td align="char" char="." valign="bottom">0.592</td><td align="char" char="." valign="bottom"><bold>1.11 (1.01, 1.21</bold>)</td><td align="char" char="." valign="bottom"><bold>0.022</bold></td><td align="left" valign="bottom">1.11 (0.93, 1.34)</td><td align="char" char="." valign="bottom">0.25</td><td align="char" char="." valign="bottom">0.96 (0.86, 1.08)</td><td align="char" char="." valign="bottom">0.524</td><td align="char" char="." valign="bottom">0.99 (0.65, 1.5)</td><td align="char" char="." valign="bottom">0.957</td></tr><tr><td align="char" char="." valign="bottom">643</td><td align="left" valign="bottom">Excessive vomiting in pregnancy</td><td align="char" char="." valign="bottom">4314</td><td align="char" char="." valign="bottom">10470323</td><td align="left" valign="bottom"><bold>0.91 (0.85, 0.97</bold>)</td><td align="char" char="." valign="bottom"><bold>0.005</bold></td><td align="char" char="." valign="bottom"><bold>1.17 (1.08, 1.27</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">1.12 (0.83, 1.51)</td><td align="char" char="." valign="bottom">0.48</td><td align="char" char="." valign="bottom">1 (0.87, 1.14)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">1 (0.89, 1.11)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">643.1</td><td align="left" valign="bottom">Hyperemesis gravidarum</td><td align="char" char="." valign="bottom">3558</td><td align="char" char="." valign="bottom">10488446</td><td align="left" valign="bottom"><bold>0.9 (0.84, 0.96</bold>)</td><td align="char" char="." valign="bottom"><bold>0.002</bold></td><td align="char" char="." valign="bottom">1.15 (0.97, 1.37)</td><td align="char" char="." valign="bottom">0.105</td><td align="left" valign="bottom">1.11 (0.91, 1.37)</td><td align="char" char="." valign="bottom">0.313</td><td align="char" char="." valign="bottom">1.01 (0.76, 1.36)</td><td align="char" char="." valign="bottom">0.927</td><td align="char" char="." valign="bottom">1.05 (0.78, 1.4)</td><td align="char" char="." valign="bottom">0.777</td></tr><tr><td align="char" char="." valign="bottom">647.3</td><td align="left" valign="bottom">Major puerperal infection</td><td align="char" char="." valign="bottom">274</td><td align="char" char="." valign="bottom">10504689</td><td align="left" valign="bottom">1.04 (0.34, 3.13)</td><td align="char" char="." valign="bottom">0.952</td><td align="char" char="." valign="bottom">1.37 (0.98, 1.92)</td><td align="char" char="." valign="bottom">0.068</td><td align="left" valign="bottom">0.78 (0.25, 2.45)</td><td align="char" char="." valign="bottom">0.688</td><td align="char" char="." valign="bottom">0.86 (0.59, 1.25)</td><td align="char" char="." valign="bottom">0.439</td><td align="char" char="." valign="bottom"><bold>0.72 (0.56, 0.93</bold>)</td><td align="char" char="." valign="bottom"><bold>0.01</bold></td></tr><tr><td align="char" char="." valign="bottom">649.1</td><td align="left" valign="bottom">Diabetes or abnormal glucose tolerance complicating pregnancy</td><td align="char" char="." valign="bottom">5053</td><td align="char" char="." valign="bottom">10480682</td><td align="left" valign="bottom">0.92 (0.64, 1.33)</td><td align="char" char="." valign="bottom">0.679</td><td align="char" char="." valign="bottom">1.22 (0.95, 1.56)</td><td align="char" char="." valign="bottom">0.118</td><td align="left" valign="bottom">1.17 (0.75, 1.82)</td><td align="char" char="." valign="bottom">0.504</td><td align="char" char="." valign="bottom">0.95 (0.55, 1.64)</td><td align="char" char="." valign="bottom">0.866</td><td align="char" char="." valign="bottom"><bold>1.26 (1.03, 1.55</bold>)</td><td align="char" char="." valign="bottom"><bold>0.026</bold></td></tr><tr><td align="char" char="." valign="bottom">654.1</td><td align="left" valign="bottom">Abnormality of organs and soft tissues of pelvis complicating pregnancy, childbirth, or the puerperium</td><td align="char" char="." valign="bottom">5842</td><td align="char" char="." valign="bottom">10479533</td><td align="left" valign="bottom"><bold>0.94 (0.89, 0.99</bold>)</td><td align="char" char="." valign="bottom"><bold>0.016</bold></td><td align="char" char="." valign="bottom"><bold>1.09 (1.01, 1.16</bold>)</td><td align="char" char="." valign="bottom"><bold>0.019</bold></td><td align="left" valign="bottom">0.93 (0.76, 1.13)</td><td align="char" char="." valign="bottom">0.467</td><td align="char" char="." valign="bottom">1.04 (0.96, 1.12)</td><td align="char" char="." valign="bottom">0.378</td><td align="char" char="." valign="bottom"><bold>1.08 (1.01, 1.16</bold>)</td><td align="char" char="." valign="bottom"><bold>0.03</bold></td></tr><tr><td align="char" char="." valign="bottom">654.2</td><td align="left" valign="bottom">Rhesus isoimmunization in pregnancy</td><td align="char" char="." valign="bottom">808</td><td align="char" char="." valign="bottom">10503190</td><td align="left" valign="bottom">1.12 (0.91, 1.38)</td><td align="char" char="." valign="bottom">0.294</td><td align="char" char="." valign="bottom">0.8 (0.61, 1.06)</td><td align="char" char="." valign="bottom">0.118</td><td align="left" valign="bottom">0.82 (0.4, 1.71)</td><td align="char" char="." valign="bottom">0.612</td><td align="char" char="." valign="bottom">1.01 (0.65, 1.57)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom"><bold>0.26 (0.24, 0.29</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="char" char="." valign="bottom">656.1</td><td align="left" valign="bottom">Isoimmunization of fetus or newborn</td><td align="char" char="." valign="bottom">508</td><td align="char" char="." valign="bottom">482914*</td><td align="left" valign="bottom"><bold>2.6 (1.57, 4.33)**</bold></td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.57 (0.53, 4.61)**</td><td align="char" char="." valign="bottom">0.42</td><td align="left" valign="bottom">0.4 (0.01, 11.01)**</td><td align="char" char="." valign="bottom">0.599</td><td align="char" char="." valign="bottom"><bold>0.24 (0.11, 0.51)**</bold></td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">1.03 (0.21, 5.13)**</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td colspan="14" style="author-callout-style-b8"><bold>Dermatologic</bold></td></tr><tr><td align="char" char="." valign="bottom">704</td><td align="left" valign="bottom">Diseases of hair and hair follicles</td><td align="char" char="." valign="bottom">4102</td><td align="char" char="." valign="bottom">17578353</td><td align="left" valign="bottom">0.99 (0.62, 1.59)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom"><bold>1.18 (1.04, 1.34</bold>)</td><td align="char" char="." valign="bottom"><bold>0.01</bold></td><td align="left" valign="bottom">1.03 (0.25, 4.3)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.93 (0.82, 1.06)</td><td align="char" char="." valign="bottom">0.273</td><td align="char" char="." valign="bottom">1.04 (0.68, 1.59)</td><td align="char" char="." valign="bottom">0.876</td></tr><tr><td align="char" char="." valign="bottom">704.2</td><td align="left" valign="bottom">Hirsutism</td><td align="char" char="." valign="bottom">1778</td><td align="char" char="." valign="bottom">17608888</td><td align="left" valign="bottom">0.94 (0.7, 1.26)</td><td align="char" char="." valign="bottom">0.688</td><td align="char" char="." valign="bottom"><bold>1.32 (1.15, 1.5</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">1.26 (0.96, 1.65)</td><td align="char" char="." valign="bottom">0.093</td><td align="char" char="." valign="bottom">0.88 (0.75, 1.04)</td><td align="char" char="." valign="bottom">0.13</td><td align="char" char="." valign="bottom">1.13 (0.87, 1.45)</td><td align="char" char="." valign="bottom">0.369</td></tr><tr><td align="char" char="." valign="bottom">707</td><td align="left" valign="bottom">Chronic ulcer of skin</td><td align="char" char="." valign="bottom">2121</td><td align="char" char="." valign="bottom">17617533</td><td align="left" valign="bottom">0.94 (0.74, 1.19)</td><td align="char" char="." valign="bottom">0.617</td><td align="char" char="." valign="bottom"><bold>1.23 (1.04, 1.47</bold>)</td><td align="char" char="." valign="bottom"><bold>0.017</bold></td><td align="left" valign="bottom">0.94 (0.29, 3.07)</td><td align="char" char="." valign="bottom">0.927</td><td align="char" char="." valign="bottom">0.98 (0.51, 1.88)</td><td align="char" char="." valign="bottom">0.959</td><td align="char" char="." valign="bottom">1.01 (0.59, 1.74)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td colspan="14" style="author-callout-style-b8"><bold>Musculoskeletal</bold></td></tr><tr><td align="char" char="." valign="bottom">722.7</td><td align="left" valign="bottom">Intervertebral disc disorder with myelopathy</td><td align="char" char="." valign="bottom">747</td><td align="char" char="." valign="bottom">17625461</td><td align="left" valign="bottom">0.95 (0.61, 1.47)</td><td align="char" char="." valign="bottom">0.82</td><td align="char" char="." valign="bottom"><bold>1.26 (1.01, 1.59</bold>)</td><td align="char" char="." valign="bottom"><bold>0.042</bold></td><td align="left" valign="bottom">0.65 (0.31, 1.35)</td><td align="char" char="." valign="bottom">0.248</td><td align="char" char="." valign="bottom">1.01 (0.58, 1.76)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.97 (0.28, 3.31)</td><td align="char" char="." valign="bottom">0.961</td></tr><tr><td align="char" char="." valign="bottom">727</td><td align="left" valign="bottom">Other disorders of synovium, tendon, and bursa</td><td align="char" char="." valign="bottom">30487</td><td align="char" char="." valign="bottom">17272753</td><td align="left" valign="bottom">1.02 (0.95, 1.09)</td><td align="char" char="." valign="bottom">0.627</td><td align="char" char="." valign="bottom"><bold>0.94 (0.89, 0.99</bold>)</td><td align="char" char="." valign="bottom"><bold>0.016</bold></td><td align="left" valign="bottom">0.99 (0.57, 1.7)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">1.01 (0.92, 1.11)</td><td align="char" char="." valign="bottom">0.809</td><td align="char" char="." valign="bottom">0.97 (0.9, 1.04)</td><td align="char" char="." valign="bottom">0.352</td></tr><tr><td align="char" char="." valign="bottom">727.7</td><td align="left" valign="bottom">Contracture of tendon (sheath)</td><td align="char" char="." valign="bottom">391</td><td align="char" char="." valign="bottom">17628006</td><td align="left" valign="bottom">0.91 (0.45, 1.84)</td><td align="char" char="." valign="bottom">0.8</td><td align="char" char="." valign="bottom">1.14 (0.38, 3.43)</td><td align="char" char="." valign="bottom">0.826</td><td align="left" valign="bottom">1.11 (0.05, 24.01)</td><td align="char" char="." valign="bottom">0.951</td><td align="char" char="." valign="bottom">1.02 (0.46, 2.25)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom"><bold>0.65 (0.47, 0.9</bold>)</td><td align="char" char="." valign="bottom"><bold>0.009</bold></td></tr><tr><td align="char" char="." valign="bottom">728</td><td align="left" valign="bottom">Disorders of muscle, ligament, and fascia</td><td align="char" char="." valign="bottom">11338</td><td align="char" char="." valign="bottom">17510763</td><td align="left" valign="bottom"><bold>1.08 (1.02, 1.13</bold>)</td><td align="char" char="." valign="bottom"><bold>0.008</bold></td><td align="char" char="." valign="bottom">0.93 (0.83, 1.04)</td><td align="char" char="." valign="bottom">0.199</td><td align="left" valign="bottom">0.88 (0.74, 1.05)</td><td align="char" char="." valign="bottom">0.164</td><td align="char" char="." valign="bottom">0.98 (0.85, 1.12)</td><td align="char" char="." valign="bottom">0.766</td><td align="char" char="." valign="bottom">0.93 (0.85, 1.01)</td><td align="char" char="." valign="bottom">0.085</td></tr><tr><td align="char" char="." valign="bottom">740</td><td align="left" valign="bottom">Osteoarthrosis</td><td align="char" char="." valign="bottom">53711</td><td align="char" char="." valign="bottom">17187748</td><td align="left" valign="bottom">1.01 (0.94, 1.09)</td><td align="char" char="." valign="bottom">0.815</td><td align="char" char="." valign="bottom"><bold>0.95 (0.9, 0.99</bold>)</td><td align="char" char="." valign="bottom"><bold>0.021</bold></td><td align="left" valign="bottom">1.02 (0.79, 1.31)</td><td align="char" char="." valign="bottom">0.911</td><td align="char" char="." valign="bottom">1.01 (0.93, 1.1)</td><td align="char" char="." valign="bottom">0.838</td><td align="char" char="." valign="bottom">0.97 (0.92, 1.01)</td><td align="char" char="." valign="bottom">0.132</td></tr><tr><td align="char" char="." valign="bottom">740.11</td><td align="left" valign="bottom">Osteoarthrosis, localized, primary</td><td align="char" char="." valign="bottom">40386</td><td align="char" char="." valign="bottom">17333061</td><td align="left" valign="bottom">1.01 (0.94, 1.09)</td><td align="char" char="." valign="bottom">0.779</td><td align="char" char="." valign="bottom"><bold>0.94 (0.9, 0.99</bold>)</td><td align="char" char="." valign="bottom"><bold>0.012</bold></td><td align="left" valign="bottom">0.99 (0.72, 1.35)</td><td align="char" char="." valign="bottom">0.94</td><td align="char" char="." valign="bottom">1.01 (0.95, 1.08)</td><td align="char" char="." valign="bottom">0.663</td><td align="char" char="." valign="bottom">0.97 (0.92, 1.02)</td><td align="char" char="." valign="bottom">0.188</td></tr><tr><td align="char" char="." valign="bottom">741</td><td align="left" valign="bottom">Symptoms and disorders of the joints</td><td align="char" char="." valign="bottom">5085</td><td align="char" char="." valign="bottom">17578450</td><td align="left" valign="bottom">0.99 (0.66, 1.48)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom"><bold>0.85 (0.73, 0.99</bold>)</td><td align="char" char="." valign="bottom"><bold>0.032</bold></td><td align="left" valign="bottom">0.93 (0.52, 1.69)</td><td align="char" char="." valign="bottom">0.83</td><td align="char" char="." valign="bottom">1.09 (0.99, 1.2)</td><td align="char" char="." valign="bottom">0.072</td><td align="char" char="." valign="bottom">1 (0.82, 1.24)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">742</td><td align="left" valign="bottom">Derangement of joint, non-traumatic</td><td align="char" char="." valign="bottom">16652</td><td align="char" char="." valign="bottom">17438176</td><td align="left" valign="bottom">1.03 (0.96, 1.11)</td><td align="char" char="." valign="bottom">0.357</td><td align="char" char="." valign="bottom"><bold>0.9 (0.83, 0.97</bold>)</td><td align="char" char="." valign="bottom"><bold>0.004</bold></td><td align="left" valign="bottom">0.98 (0.61, 1.56)</td><td align="char" char="." valign="bottom">0.924</td><td align="char" char="." valign="bottom">1.02 (0.88, 1.17)</td><td align="char" char="." valign="bottom">0.838</td><td align="char" char="." valign="bottom">0.95 (0.87, 1.04)</td><td align="char" char="." valign="bottom">0.291</td></tr><tr><td align="char" char="." valign="bottom">742.9</td><td align="left" valign="bottom">Other derangement of joint</td><td align="char" char="." valign="bottom">13669</td><td align="char" char="." valign="bottom">17490182</td><td align="left" valign="bottom">1.02 (0.9, 1.16)</td><td align="char" char="." valign="bottom">0.757</td><td align="char" char="." valign="bottom"><bold>0.91 (0.83, 0.99</bold>)</td><td align="char" char="." valign="bottom"><bold>0.023</bold></td><td align="left" valign="bottom">0.98 (0.47, 2.06)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">1.02 (0.91, 1.15)</td><td align="char" char="." valign="bottom">0.714</td><td align="char" char="." valign="bottom">0.95 (0.86, 1.04)</td><td align="char" char="." valign="bottom">0.26</td></tr><tr><td align="char" char="." valign="bottom">743</td><td align="left" valign="bottom">Osteoporosis, osteopenia and pathological fracture</td><td align="char" char="." valign="bottom">15875</td><td align="char" char="." valign="bottom">17536424</td><td align="left" valign="bottom"><bold>1.05 (1, 1.11</bold>)</td><td align="char" char="." valign="bottom"><bold>0.049</bold></td><td align="char" char="." valign="bottom">0.94 (0.85, 1.05)</td><td align="char" char="." valign="bottom">0.26</td><td align="left" valign="bottom">0.92 (0.76, 1.12)</td><td align="char" char="." valign="bottom">0.405</td><td align="char" char="." valign="bottom">0.99 (0.85, 1.14)</td><td align="char" char="." valign="bottom">0.858</td><td align="char" char="." valign="bottom">1 (0.98, 1.02)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">743.11</td><td align="left" valign="bottom">Osteoporosis NOS</td><td align="char" char="." valign="bottom">13633</td><td align="char" char="." valign="bottom">17553976</td><td align="left" valign="bottom"><bold>1.06 (1.02, 1.1</bold>)</td><td align="char" char="." valign="bottom"><bold>0.003</bold></td><td align="char" char="." valign="bottom"><bold>0.93 (0.87, 1</bold>)</td><td align="char" char="." valign="bottom"><bold>0.039</bold></td><td align="left" valign="bottom">0.94 (0.78, 1.13)</td><td align="char" char="." valign="bottom">0.514</td><td align="char" char="." valign="bottom">0.98 (0.9, 1.07)</td><td align="char" char="." valign="bottom">0.68</td><td align="char" char="." valign="bottom">1 (0.82, 1.21)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td colspan="14" style="author-callout-style-b8"><bold>Congenital Anomalies</bold></td></tr><tr><td align="char" char="." valign="bottom">747</td><td align="left" valign="bottom">Cardiac and circulatory congenital anomalies</td><td align="char" char="." valign="bottom">15297</td><td align="char" char="." valign="bottom">482914*</td><td align="left" valign="bottom"><bold>1.07 (1.01, 1.14)**</bold></td><td align="char" char="." valign="bottom"><bold>0.029</bold></td><td align="char" char="." valign="bottom">0.94 (0.8, 1.11)**</td><td align="char" char="." valign="bottom">0.475</td><td align="left" valign="bottom">1.02 (0.47, 2.23)**</td><td align="char" char="." valign="bottom">0.961</td><td align="char" char="." valign="bottom">0.95 (0.88, 1.03)**</td><td align="char" char="." valign="bottom">0.223</td><td align="char" char="." valign="bottom">0.98 (0.77, 1.25)**</td><td align="char" char="." valign="bottom">0.884</td></tr><tr><td align="char" char="." valign="bottom">747.1</td><td align="left" valign="bottom">Cardiac congenital anomalies</td><td align="char" char="." valign="bottom">1621</td><td align="char" char="." valign="bottom">482914*</td><td align="left" valign="bottom"><bold>1.19 (1.02, 1.39)**</bold></td><td align="char" char="." valign="bottom"><bold>0.023</bold></td><td align="char" char="." valign="bottom"><bold>0.77 (0.6, 0.98)**</bold></td><td align="char" char="." valign="bottom"><bold>0.036</bold></td><td align="left" valign="bottom">1.03 (0.27, 3.86)**</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.93 (0.69, 1.25)**</td><td align="char" char="." valign="bottom">0.635</td><td align="char" char="." valign="bottom">1.02 (0.48, 2.16)**</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">755</td><td align="left" valign="bottom">Congenital anomalies of limbs</td><td align="char" char="." valign="bottom">6557</td><td align="char" char="." valign="bottom">482914*</td><td align="left" valign="bottom">0.99 (0.65, 1.5)**</td><td align="char" char="." valign="bottom">0.957</td><td align="char" char="." valign="bottom">0.96 (0.71, 1.29)**</td><td align="char" char="." valign="bottom">0.778</td><td align="left" valign="bottom">0.96 (0.46, 1.97)**</td><td align="char" char="." valign="bottom">0.91</td><td align="char" char="." valign="bottom">1.04 (0.89, 1.23)**</td><td align="char" char="." valign="bottom">0.627</td><td align="char" char="." valign="bottom"><bold>0.88 (0.8, 0.97)**</bold></td><td align="char" char="." valign="bottom"><bold>0.013</bold></td></tr><tr><td align="char" char="." valign="bottom">755.61</td><td align="left" valign="bottom">Congenital hip dysplasia and deformity</td><td align="char" char="." valign="bottom">2823</td><td align="char" char="." valign="bottom">482914*</td><td align="left" valign="bottom">1.01 (0.57, 1.78)**</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.87 (0.66, 1.16)**</td><td align="char" char="." valign="bottom">0.355</td><td align="left" valign="bottom">0.89 (0.42, 1.88)**</td><td align="char" char="." valign="bottom">0.766</td><td align="char" char="." valign="bottom">1.07 (0.85, 1.35)**</td><td align="char" char="." valign="bottom">0.57</td><td align="char" char="." valign="bottom"><bold>0.81 (0.71, 0.94)**</bold></td><td align="char" char="." valign="bottom"><bold>0.004</bold></td></tr></tbody></table><table-wrap-foot><fn><p>a. Statistically significant IRRs are marked with bold (FDR adjusted <italic>P</italic>-value &lt;0.05).</p></fn><fn><p>b. The IRRs are adjusted for age, sex, interaction between age and sex, and birth year.</p></fn><fn><p>c. All other ABO blood groups and the RhD negative blood group was used as a reference, respectively.</p></fn><fn><p>d. FDR-adjusted p-values and 95% confidence intervals are presented.</p></fn><fn><p>e. FDR adjusted p-values above 0.97 were set to 0.97 to avoid exploding adjusted confidence intervals.</p></fn><fn><p>e. Phecodes are divided by PheWAS disease categories.</p></fn><fn><p>f. The number of events and the follow-up time in person-years for each phecode is presented.</p></fn><fn><p>g. For study results of congenital phecodes estimates marked with ** are prevalence ratios instead of IRRs and the corresponding person-year marked with * are the size of the cohort.</p></fn></table-wrap-foot></table-wrap><p>The number of statistically significant IRRs for A, B, AB, O, and RhD were 50, 38, 11, 53, and 28, respectively. However, a between blood group comparison on the number of statistically significant IRRs is problematic because the analyses of blood group A and O had the highest power given that these blood groups were most frequent in the study sample (<xref ref-type="table" rid="table1">Table 1</xref>). For 13 phecodes, an association was found for both the ABO blood group and the RhD blood group. The ABO blood groups were found positively associated with 75 phecodes and inversely associated with 67 phecodes. The RhD-positive blood group was found to have 16 positive- and 12 inverse associations. Blood groups A and O were associated with diseases of the circulatory and digestive system. Blood group B was associated with several infectious, metabolic, and musculoskeletal diseases. The associations of the RhD blood group included cancers, infectious diseases, and pregnancy complications. The results of the supplementary analyses where blood group O was used as the reference is shown in <xref ref-type="supplementary-material" rid="supp6 supp7">Supplementary files 6 and 7</xref>.</p></sec><sec id="s3-2"><title>Age at first diagnosis</title><p>We found the B blood group to be associated with a later diagnosis of viral infection. Further, blood group O was associated with a later diagnosis of phlebitis and thrombophlebitis (<xref ref-type="table" rid="table3">Table 3</xref> and <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). The RhD-positive group was associated with a later diagnosis of acute and chronic tonsilitis diagnosis.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Statistically significant associations between the ABO/RhD blood groups and the age of the first diagnosis.</title><p><supplementary-material id="table3sdata1"><label>Table 3—source data 1.</label><caption><title>Associations between the ABO/RhD blood groups and the age of the first diagnosis.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83116-table3-data1-v2.zip"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="3"/><th align="left" valign="bottom" colspan="2">Blood group A</th><th align="left" valign="bottom" colspan="2">Blood group B</th><th align="left" valign="bottom" colspan="2">Blood group AB</th><th align="left" valign="bottom" colspan="2">Blood group 0</th><th align="left" valign="bottom" colspan="2">Blood group RhD</th></tr><tr><th align="left" valign="bottom">Phecode</th><th align="left" valign="bottom">Phenotype</th><th align="left" valign="bottom">N</th><th align="left" valign="bottom">Estimate (95% CI)</th><th align="left" valign="bottom">p-value</th><th align="left" valign="bottom">Estimate (95% CI)</th><th align="left" valign="bottom">p-value</th><th align="left" valign="bottom">Estimate (95% CI)</th><th align="left" valign="bottom">p-value</th><th align="left" valign="bottom">Estimate (95% CI)</th><th align="left" valign="bottom">p-value</th><th align="left" valign="bottom">Estimate (95% CI)</th><th align="left" valign="bottom">p-value</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">079</td><td align="left" valign="bottom">Viral infection</td><td align="char" char="." valign="bottom">25075</td><td align="char" char="." valign="bottom">–0.26 (–3.06, 2.54)</td><td align="char" char="." valign="bottom">0.864</td><td align="char" char="." valign="bottom"><bold>0.92 (0.13, 1.71</bold>)</td><td align="char" char="." valign="bottom"><bold>0.022</bold></td><td align="char" char="." valign="bottom">0.53 (–6.18, 7.23)</td><td align="char" char="." valign="bottom">0.887</td><td align="char" char="." valign="bottom">–0.23 (–3.22, 2.75)</td><td align="char" char="." valign="bottom">0.887</td><td align="char" char="." valign="bottom">0.27 (–5.22, 5.75)</td><td align="char" char="." valign="bottom">0.93</td></tr><tr><td align="char" char="." valign="bottom">451</td><td align="left" valign="bottom">Phlebitis and thrombophlebitis</td><td align="char" char="." valign="bottom">16748</td><td align="char" char="." valign="bottom">–<bold>0.58 (–1.02,–0.13</bold>)</td><td align="char" char="." valign="bottom"><bold>0.011</bold></td><td align="char" char="." valign="bottom">–0.24 (–5.71, 5.22)</td><td align="char" char="." valign="bottom">0.936</td><td align="char" char="." valign="bottom">–0.6 (–5.87, 4.66)</td><td align="char" char="." valign="bottom">0.833</td><td align="char" char="." valign="bottom"><bold>0.91 (0.57, 1.25</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.01 (–0.33, 0.34)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">451.2</td><td align="left" valign="bottom">Phlebitis and thrombophlebitis of lower extremities</td><td align="char" char="." valign="bottom">15650</td><td align="char" char="." valign="bottom">–0.53 (–1.08, 0.01)</td><td align="char" char="." valign="bottom">0.055</td><td align="char" char="." valign="bottom">–0.27 (–5.85, 5.31)</td><td align="char" char="." valign="bottom">0.93</td><td align="char" char="." valign="bottom">–0.7 (–6.35, 4.95)</td><td align="char" char="." valign="bottom">0.82</td><td align="char" char="." valign="bottom"><bold>0.9 (0.55, 1.25</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.08 (–3.89, 4.06)</td><td align="char" char="." valign="bottom">0.97</td></tr><tr><td align="char" char="." valign="bottom">474</td><td align="left" valign="bottom">Acute and chronic tonsillitis</td><td align="char" char="." valign="bottom">41428</td><td align="char" char="." valign="bottom">–0.29 (–1.45, 0.87)</td><td align="char" char="." valign="bottom">0.634</td><td align="char" char="." valign="bottom">0.42 (–1.97, 2.8)</td><td align="char" char="." valign="bottom">0.744</td><td align="char" char="." valign="bottom">0.38 (–5.71, 6.48)</td><td align="char" char="." valign="bottom">0.909</td><td align="char" char="." valign="bottom">0.05 (–2.15, 2.24)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom"><bold>0.67 (0.15, 1.19</bold>)</td><td align="char" char="." valign="bottom"><bold>0.011</bold></td></tr><tr><td align="char" char="." valign="bottom">474.1</td><td align="left" valign="bottom">Acute tonsillitis</td><td align="char" char="." valign="bottom">18162</td><td align="char" char="." valign="bottom">0.1 (–4.42, 4.61)</td><td align="char" char="." valign="bottom">0.97</td><td align="char" char="." valign="bottom">0.41 (–7.17, 7.98)</td><td align="char" char="." valign="bottom">0.923</td><td align="char" char="." valign="bottom">0.75 (–7.23, 8.74)</td><td align="char" char="." valign="bottom">0.864</td><td align="char" char="." valign="bottom">–0.42 (–3.76, 2.93)</td><td align="char" char="." valign="bottom">0.82</td><td align="char" char="." valign="bottom"><bold>1.34 (0.64, 2.04</bold>)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td></tr></tbody></table><table-wrap-foot><fn><p>a. Statistically significant effect estimates are marked with bold (FDR adjusted <italic>P</italic>-value &lt;0.05).</p></fn><fn><p>b. FDR adjusted p-values and 95% confidence intervals are presented.</p></fn><fn><p>c. FDR adjusted p-values above 0.97 were set to 0.97 to enable estimation of adjusted confidence intervals.</p></fn><fn><p>d. Estimates represent increases or decreases in years of age of first diagnosis.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>We found the ABO/RhD blood groups to be associated with a wide spectrum of diseases including cancers and musculoskeletal-, genitourinary-, endocrinal-, infectious-, cardiovascular-, and gastrointestinal diseases. Associations of the ABO blood groups included monocytic leukemia, tonsilitis, renal dialysis, diseases of the female reproductive system, and osteoarthrosis. Associations of the RhD blood group included cancer of the tongue, malignant neoplasm (other), tuberculosis-, HIV-, hepatitis B infection, type 2 diabetes, hereditary hemolytic anemias, major puerperal infection, anxiety disorders, and contracture of tendon.</p><p>The blood groups may reflect their corresponding genetic markers; thus, our findings may indicate an association between disease and the ABO locus on chromosome 9 and the RH locus on chromosome 1, respectively. Alternatively, the associations may indicate that the blood groups are involved in disease mechanisms at the molecular level mediated either through the blood group antigens or by the blood group reactive antibodies. However, our findings have a compromised causal interpretation given the retrospective inclusion of individuals (and person-time) after an in-hospital blood group test.</p><p>Our results support several previously observed associations including positive associations between the non-O blood groups and prothrombotic diseases of the circulatory system (phecodes: 411.1–459.9), associations with gastroduodenal ulcers, associations of blood group O and lower risk of type 2 diabetes, and positive association between blood group B and tuberculosis (<xref ref-type="bibr" rid="bib27">Vasan et al., 2016</xref>; <xref ref-type="bibr" rid="bib11">Edgren et al., 2010</xref>; <xref ref-type="bibr" rid="bib7">Dahlén et al., 2021</xref>; <xref ref-type="bibr" rid="bib13">Fagherazzi et al., 2015</xref>; <xref ref-type="bibr" rid="bib24">Rao, 2012</xref>). Further, our results support findings associating non-O blood groups with increased risk of pancreatic cancer (<xref ref-type="bibr" rid="bib20">Liumbruno and Franchini, 2014</xref>). The role of the ABO blood group in HIV susceptibility remains controversial; we only observed a positive association for the RhD-positive blood group (<xref ref-type="bibr" rid="bib8">Davison et al., 2020</xref>).</p><p>We found blood group B to be positively associated with ‘ectopic pregnancy’, ‘excessive vomiting in pregnancy, and ‘abnormality of organs and soft tissues of pelvis complicating pregnancy’ indicating that blood group B mothers may be more likely to experience pregnancy complications. Further, we found positive associations of blood group A with both ‘mucous polyp of cervix’, and blood group AB with ‘cervicitis and endocervicitis’. Taken together these findings may indicate that the ABO blood groups are associated with diseases of the female reproductive system. However, the study design does not allow for any causal interpretation.</p><p>Only a few statistically significant associations were found for the analyses of the age of the first diagnosis; thus, indicating that the blood group’s involvement in disease onset may be marginal. However, we assumed a linear relationship with age because assessing potential non-linear relationships for each disease would be unfeasible given the large number of tests performed. The linearity assumption may not hold for all analyses which limits the interpretation of the estimates.</p><p>A strength of our approach is that we utilized the phecode disease classification scheme that is specifically developed for disease-wide risk analyses (<xref ref-type="bibr" rid="bib31">Wu et al., 2019</xref>) The phecode mapping scheme combines ICD-10 codes that clinical domain experts have deemed to cover the same disease. For example, respiratory tuberculosis (A16), tuberculosis of nervous system (A17), and miliary tuberculosis (A19), are combined into the phecode tuberculosis (phecode 10). Phecodes may therefore provide increased power and precision compared with using ICD-10 categories (<xref ref-type="bibr" rid="bib9">Denny et al., 2010</xref>). Further, contrary to previous studies, we compared each blood group to all other blood groups, instead of determining effect estimates relative to blood group O. Thus, here we better capture the uniqueness of each individual ABO blood group.</p><sec id="s4-1"><title>Limitations</title><p>Our study has some important limitations, firstly, the retrospective inclusion of patients and person-time may have introduced an immortal time bias from deaths before enrollment (in-hospital ABO/RhD blood group test) (<xref ref-type="bibr" rid="bib32">Yadav and Lewis, 2021</xref>). The findings are therefore conditioned on patients surviving until the enrollment period. This implies, for example, that if a specific blood group causes a higher incidence of a deadly disease, then patients with such blood group are more likely to have died before enrollment, and therefore fewer individuals having both that blood group and the disease will be present in our cohort. If so, the direction of the estimates for deadly diseases strongly related to any blood group will have been lowered or even flipped, relative to any causal relationship. The study design, however, enabled 41 year of follow-up and was deemed reasonable because the blood groups have not been associated with mortality differences. Moreover, the blood group distribution in our cohort was found to be almost identical to a reference population of 2.2 million Danish blood donors. Further, we replicated several findings of associations between the blood groups and severe diseases, including pancreatic cancer (<xref ref-type="bibr" rid="bib27">Vasan et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Liumbruno and Franchini, 2014</xref>). This may indicate that the potential bias was less prevalent. Further, by controlling for year of birth, the potential effects of immortal time bias were likely reduced, however, this could not be tested. Immortal time biases are potentially applicable in many biobanks studies, e.g. when using the UK Biobank for retrospective studies (<xref ref-type="bibr" rid="bib32">Yadav and Lewis, 2021</xref>).</p><p>The generalizability of our findings is limited further because our cohort solely included hospitalized patients with known ABO and RhD blood groups. These are patients whom the treating doctor has deemed likely to potentially require a blood transfusion during hospitalization. The patients under study might therefore suffer from other diseases than patients without a determined blood group, and than never hospitalized individuals. Further, diseases that do not require hospitalization could not be examined. If the effect sizes are modified by factors which are more common in our cohort than in the general population then the estimates may not be generalizable. However, it is unclear if such effect modifier exists. Lastly, it was not possible to adjust for possible confounding from the geographical distribution or ethnicity of the patients (<xref ref-type="bibr" rid="bib2">Anstee, 2010</xref>). This may have biased some estimates because the distribution of blood groups varies between ethnicities while ethnicity is also associated with differences in disease susceptibility. Particularly, ethnicity has been associated with differences in prevalence of infectious-, cardiovascular-, sickle cell disease, and thasalamia (<xref ref-type="bibr" rid="bib18">Kurian and Cardarelli, 2007</xref>; <xref ref-type="bibr" rid="bib21">McQuillan et al., 2004</xref>). Thus, the estimate of these disease groups should be interpreted with caution. The Danish population is however quite homogenous and approximately 94% of Danes have European ancestry (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Therefore, a potential bias from ethnicity may be less prevalent in our cohort as compared with studies in populations of more admixed origin.</p><p>In conclusion, we found the ABO/RhD blood groups to be associated with a wide spectrum of diseases, including cardiovascular-, infectious-, gastrointestinal- and musculoskeletal diseases. This may indicate that some of the potential selective pressure on the blood groups can be attributed to disease susceptibility differences. We found few associations between the blood groups and age of first diagnosis.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>has received grants from the AP Møller Foundation, Innovation Fund Denmark and Novo Nordisk Foundation. The author has been issued the following patents: Publication no: 20110201553, 20110268732, 20130040898, 20130261177, 20150057325, 20160113891, 9381166, 9381243, 20160250164, 9433589, 20160303040 and US20090053193A1. PI Johansson reports ownership of stocks in Trial-Lab AB, Endothel Pharma ApS, TissueLink ApS, and MoxieLab ApS. PI Johansson declares that the financial interests listed have no impact on the submitted work. The author has no other competing interests to declare. The author declares that the financial interests listed have no impact on the submitted work</p></fn><fn fn-type="COI-statement" id="conf3"><p>participates on the Danish National Genome Center advisory board and is the Chairman for the data infrastructure board. The author has stock in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S and ALK Abello. The author participates on the board of directors for both Proscion A/S and Intomics A/S. The author has no other competing interests to declare. SB declares that the financial interests listed have no impact on the submitted work</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Resources, Supervision, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: This is a register-based study and informed consent for such studies is waived by the Danish Data Protection Agency. Data access was approved by the Danish Patient Safety Authority (3-3013-1731), the Danish Data Protection Agency (DT SUND 2016-50 and 2017-57) and the Danish Health Data Authority (FSEID 00003092 and FSEID 00003724).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Population at the first day of the quarter by region and country of origin.</title></caption><media xlink:href="elife-83116-supp1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>List of Phecodes defined as congenital or hereditary.</title></caption><media xlink:href="elife-83116-supp2-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>The study sample birth year distribution.</title></caption><media xlink:href="elife-83116-supp3-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Associations between the ABO/RhD blood groups and Phecode incidence rate ratios of all analyzed Phecodes.</title><p>a. Statistically significant IRRs are marked with bold (FDR adjusted <italic>P</italic>-value &lt;0.05). b. The IRRs are adjusted for age, sex, interaction between age and sex, and birth year. c. All other ABO blood groups and the RhD negative blood group was used as a reference, respectively. d. The FDR adjusted p-values and 95% confidence intervals are presented. e. FDR adjusted p-values above 0.97 were set to 0.97 to avoid exploding adjusted confidence intervals. e. Phecodes are divided by PheWAS disease categories. f. The number of events and the follow-up time in person-years for each Phecode is also presented. g. For study results of congenital Phecodes estimates marked with ** are prevalence ratios instead of IRRs and the corresponding person-year marked with * are the size of the cohort.</p></caption><media xlink:href="elife-83116-supp4-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Associations between ABO/RhD blood groups and the age of the first diagnosis.</title><p>a. Statistically significant effect estimates are marked with bold (FDR adjusted <italic>P</italic>-value &lt;0.05). b. The FDR adjusted p-values and 95% confidence intervals are presented. c. FDR adjusted p-values above 0.97 were set to 0.97 to enable estimation of adjusted confidence intervals. d. Estimates represent increases or decreases in years of age of first diagnosis.</p></caption><media xlink:href="elife-83116-supp5-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Statistically significant associations for blood groups A, B and AB relative to blood group O. Further, also for RhD positive blood group relative to the RhD negative blood group.</title><p>a. Statistically significant IRRs are marked with bold (FDR adjusted <italic>P</italic>-value &lt;0.05). b. The IRRs are adjusted for age, sex, interaction between age and sex, and birth year. c. Blood group O and the RhD negative blood group was used as a reference, respectively. d. The FDR adjusted p-values and 95% confidence intervals are presented. e. FDR adjusted p-values above 0.97 were set to 0.97 to avoid exploding adjusted confidence intervals. f. Phecodes are divided by PheWAS disease categories. g. The number of events and the follow-up time in person-years for each Phecode is also presented. h. For study results of congenital Phecodes estimates marked with ** are prevalence ratios instead of IRRs and the corresponding person-year marked with * are the size of the cohort.</p></caption><media xlink:href="elife-83116-supp6-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>Associations between the ABO/RhD blood groups and Phecode incidence rate ratios of all analyzed Phecodes with blood group O and RhD negative as the reference, respectively.</title><p>a. Statistically significant IRRs are marked with bold (FDR adjusted <italic>P</italic>-value &lt;0.05). b. The IRRs are adjusted for age, sex, interaction between age and sex, and birth year. c. Blood group O and the RhD negative blood group was used as a reference, respectively. d. The FDR adjusted p-values and 95% confidence intervals are presented. e. FDR adjusted p-values above 0.97 were set to 0.97 to avoid exploding adjusted confidence intervals. f. Phecodes are divided by PheWAS disease categories. g. The number of events and the follow-up time in person-years for each Phecode is also presented. h. For study results of congenital Phecodes estimates marked with ** are prevalence ratios instead of IRRs and the corresponding person-year marked with * are the size of the cohort.</p></caption><media xlink:href="elife-83116-supp7-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83116-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Anonymized patient data was used in this study. Due to national and EU regulations, the data cannot be shared with the wider research community. However, data can be accessed upon relevant application to the Danish authorities. The Danish Patient Safety Authority and the Danish Health Data Authority have permitted the use of the data in this study; whilst currently, the appropriate authority for journal data use in research is the regional committee (&quot;Regionsråd&quot;). The statistical summary data used to create the tables and graphs are available as <xref ref-type="supplementary-material" rid="table2sdata1">Table 2—source data 1</xref> and <xref ref-type="supplementary-material" rid="table3sdata1">Table 3—source data 1</xref>. The analysis code is publicly available through <ext-link ext-link-type="uri" xlink:href="https://www.github.com/peterbruun/blood_type_study">https://www.github.com/peterbruun/blood_type_study</ext-link> (copy archived at <xref ref-type="bibr" rid="bib6">Bruun-Rasmussen, 2023</xref>).</p></sec><ack id="ack"><title>Acknowledgements</title><p>This study was performed as a part of the CAG (Clinical Academic Group) Center for Endotheliomics under the Greater Copenhagen Health Science Partners (GCHSP). Sources of Funding The study was supported by the Novo Nordisk Foundation (grants NNF14CC0001 and NNF17OC0027594) and the Innovation Fund Denmark (grant 5153-00002B). The funders played no role in the conduct of the study. Funding Novo Nordisk Foundation and the Innovation Fund Denmark</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Bland</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>How to obtain the confidence interval from a P value</article-title><source>BMJ</source><volume>343</volume><elocation-id>d2090</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.d2090</pub-id><pub-id pub-id-type="pmid">21824904</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anstee</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The relationship between blood groups and disease</article-title><source>Blood</source><volume>115</volume><fpage>4635</fpage><lpage>4643</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-01-261859</pub-id><pub-id pub-id-type="pmid">20308598</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>TDB</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Blodtypes</article-title><ext-link ext-link-type="uri" xlink:href="https://bloddonor.dk/fakta-om-blod/blodtyper/">https://bloddonor.dk/fakta-om-blod/blodtyper/</ext-link><date-in-citation iso-8601-date="2022-08-31">August 31, 2022</date-in-citation></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnkob</surname><given-names>MB</given-names></name><name><surname>Pottegård</surname><given-names>A</given-names></name><name><surname>Støvring</surname><given-names>H</given-names></name><name><surname>Haunstrup</surname><given-names>TM</given-names></name><name><surname>Homburg</surname><given-names>K</given-names></name><name><surname>Larsen</surname><given-names>R</given-names></name><name><surname>Hansen</surname><given-names>MB</given-names></name><name><surname>Titlestad</surname><given-names>K</given-names></name><name><surname>Aagaard</surname><given-names>B</given-names></name><name><surname>Møller</surname><given-names>BK</given-names></name><name><surname>Barington</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Reduced prevalence of SARS-cov-2 infection in ABO blood group O</article-title><source>Blood Advances</source><volume>4</volume><fpage>4990</fpage><lpage>4993</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2020002657</pub-id><pub-id pub-id-type="pmid">33057631</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Controlling the false discovery rate: A practical and powerful approach to multiple testing</article-title><source>Journal of the Royal Statistical Society</source><volume>57</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Bruun-Rasmussen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Blood_type_study</data-title><version designator="swh:1:rev:411336fb15b802c4a257e448d7c12f2340f01694">swh:1:rev:411336fb15b802c4a257e448d7c12f2340f01694</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:d027f7f64e09e2006445ac785e01918e880818e8;origin=https://www.github.com/peterbruun/blood_type_study;visit=swh:1:snp:c58d90c7a84f83dc8c4e8837b624967d6eb216d4;anchor=swh:1:rev:411336fb15b802c4a257e448d7c12f2340f01694">https://archive.softwareheritage.org/swh:1:dir:d027f7f64e09e2006445ac785e01918e880818e8;origin=https://www.github.com/peterbruun/blood_type_study;visit=swh:1:snp:c58d90c7a84f83dc8c4e8837b624967d6eb216d4;anchor=swh:1:rev:411336fb15b802c4a257e448d7c12f2340f01694</ext-link></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlén</surname><given-names>T</given-names></name><name><surname>Clements</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Olsson</surname><given-names>ML</given-names></name><name><surname>Edgren</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>An agnostic study of associations between ABO and rhd blood group and phenome-wide disease risk</article-title><source>eLife</source><volume>10</volume><elocation-id>65658</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.65658</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davison</surname><given-names>GM</given-names></name><name><surname>Hendrickse</surname><given-names>HL</given-names></name><name><surname>Matsha</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Do blood group antigens and the red cell membrane influence human immunodeficiency virus infection?</article-title><source>Cells</source><volume>9</volume><elocation-id>845</elocation-id><pub-id pub-id-type="doi">10.3390/cells9040845</pub-id><pub-id pub-id-type="pmid">32244465</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denny</surname><given-names>JC</given-names></name><name><surname>Ritchie</surname><given-names>MD</given-names></name><name><surname>Basford</surname><given-names>MA</given-names></name><name><surname>Pulley</surname><given-names>JM</given-names></name><name><surname>Bastarache</surname><given-names>L</given-names></name><name><surname>Brown-Gentry</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Masys</surname><given-names>DR</given-names></name><name><surname>Roden</surname><given-names>DM</given-names></name><name><surname>Crawford</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PheWAS: Demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations</article-title><source>Bioinformatics</source><volume>26</volume><fpage>1205</fpage><lpage>1210</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq126</pub-id><pub-id pub-id-type="pmid">20335276</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewey</surname><given-names>M</given-names></name><name><surname>Clayton</surname><given-names>D</given-names></name><name><surname>Hills</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Statistical models in epidemiology</article-title><source>Journal of the Royal Statistical Society. Series A Statistics in Society</source><volume>158</volume><elocation-id>343</elocation-id><pub-id pub-id-type="doi">10.2307/2983301</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edgren</surname><given-names>G</given-names></name><name><surname>Hjalgrim</surname><given-names>H</given-names></name><name><surname>Rostgaard</surname><given-names>K</given-names></name><name><surname>Norda</surname><given-names>R</given-names></name><name><surname>Wikman</surname><given-names>A</given-names></name><name><surname>Melbye</surname><given-names>M</given-names></name><name><surname>Nyrén</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study</article-title><source>American Journal of Epidemiology</source><volume>172</volume><fpage>1280</fpage><lpage>1285</lpage><pub-id pub-id-type="doi">10.1093/aje/kwq299</pub-id><pub-id pub-id-type="pmid">20937632</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellinghaus</surname><given-names>D</given-names></name><name><surname>Degenhardt</surname><given-names>F</given-names></name><name><surname>Bujanda</surname><given-names>L</given-names></name><name><surname>Buti</surname><given-names>M</given-names></name><name><surname>Albillos</surname><given-names>A</given-names></name><name><surname>Invernizzi</surname><given-names>P</given-names></name><name><surname>Fernández</surname><given-names>J</given-names></name><name><surname>Prati</surname><given-names>D</given-names></name><name><surname>Baselli</surname><given-names>G</given-names></name><name><surname>Asselta</surname><given-names>R</given-names></name><name><surname>Grimsrud</surname><given-names>MM</given-names></name><name><surname>Milani</surname><given-names>C</given-names></name><name><surname>Aziz</surname><given-names>F</given-names></name><name><surname>Kässens</surname><given-names>J</given-names></name><name><surname>May</surname><given-names>S</given-names></name><name><surname>Wendorff</surname><given-names>M</given-names></name><name><surname>Wienbrandt</surname><given-names>L</given-names></name><name><surname>Uellendahl-Werth</surname><given-names>F</given-names></name><name><surname>Zheng</surname><given-names>T</given-names></name><name><surname>Yi</surname><given-names>X</given-names></name><name><surname>de Pablo</surname><given-names>R</given-names></name><name><surname>Chercoles</surname><given-names>AG</given-names></name><name><surname>Palom</surname><given-names>A</given-names></name><name><surname>Garcia-Fernandez</surname><given-names>A-E</given-names></name><name><surname>Rodriguez-Frias</surname><given-names>F</given-names></name><name><surname>Zanella</surname><given-names>A</given-names></name><name><surname>Bandera</surname><given-names>A</given-names></name><name><surname>Protti</surname><given-names>A</given-names></name><name><surname>Aghemo</surname><given-names>A</given-names></name><name><surname>Lleo</surname><given-names>A</given-names></name><name><surname>Biondi</surname><given-names>A</given-names></name><name><surname>Caballero-Garralda</surname><given-names>A</given-names></name><name><surname>Gori</surname><given-names>A</given-names></name><name><surname>Tanck</surname><given-names>A</given-names></name><name><surname>Carreras Nolla</surname><given-names>A</given-names></name><name><surname>Latiano</surname><given-names>A</given-names></name><name><surname>Fracanzani</surname><given-names>AL</given-names></name><name><surname>Peschuck</surname><given-names>A</given-names></name><name><surname>Julià</surname><given-names>A</given-names></name><name><surname>Pesenti</surname><given-names>A</given-names></name><name><surname>Voza</surname><given-names>A</given-names></name><name><surname>Jiménez</surname><given-names>D</given-names></name><name><surname>Mateos</surname><given-names>B</given-names></name><name><surname>Nafria Jimenez</surname><given-names>B</given-names></name><name><surname>Quereda</surname><given-names>C</given-names></name><name><surname>Paccapelo</surname><given-names>C</given-names></name><name><surname>Gassner</surname><given-names>C</given-names></name><name><surname>Angelini</surname><given-names>C</given-names></name><name><surname>Cea</surname><given-names>C</given-names></name><name><surname>Solier</surname><given-names>A</given-names></name><name><surname>Pestaña</surname><given-names>D</given-names></name><name><surname>Muñiz-Diaz</surname><given-names>E</given-names></name><name><surname>Sandoval</surname><given-names>E</given-names></name><name><surname>Paraboschi</surname><given-names>EM</given-names></name><name><surname>Navas</surname><given-names>E</given-names></name><name><surname>García Sánchez</surname><given-names>F</given-names></name><name><surname>Ceriotti</surname><given-names>F</given-names></name><name><surname>Martinelli-Boneschi</surname><given-names>F</given-names></name><name><surname>Peyvandi</surname><given-names>F</given-names></name><name><surname>Blasi</surname><given-names>F</given-names></name><name><surname>Téllez</surname><given-names>L</given-names></name><name><surname>Blanco-Grau</surname><given-names>A</given-names></name><name><surname>Hemmrich-Stanisak</surname><given-names>G</given-names></name><name><surname>Grasselli</surname><given-names>G</given-names></name><name><surname>Costantino</surname><given-names>G</given-names></name><name><surname>Cardamone</surname><given-names>G</given-names></name><name><surname>Foti</surname><given-names>G</given-names></name><name><surname>Aneli</surname><given-names>S</given-names></name><name><surname>Kurihara</surname><given-names>H</given-names></name><name><surname>ElAbd</surname><given-names>H</given-names></name><name><surname>My</surname><given-names>I</given-names></name><name><surname>Galván-Femenia</surname><given-names>I</given-names></name><name><surname>Martín</surname><given-names>J</given-names></name><name><surname>Erdmann</surname><given-names>J</given-names></name><name><surname>Ferrusquía-Acosta</surname><given-names>J</given-names></name><name><surname>Garcia-Etxebarria</surname><given-names>K</given-names></name><name><surname>Izquierdo-Sanchez</surname><given-names>L</given-names></name><name><surname>Bettini</surname><given-names>LR</given-names></name><name><surname>Sumoy</surname><given-names>L</given-names></name><name><surname>Terranova</surname><given-names>L</given-names></name><name><surname>Moreira</surname><given-names>L</given-names></name><name><surname>Santoro</surname><given-names>L</given-names></name><name><surname>Scudeller</surname><given-names>L</given-names></name><name><surname>Mesonero</surname><given-names>F</given-names></name><name><surname>Roade</surname><given-names>L</given-names></name><name><surname>Rühlemann</surname><given-names>MC</given-names></name><name><surname>Schaefer</surname><given-names>M</given-names></name><name><surname>Carrabba</surname><given-names>M</given-names></name><name><surname>Riveiro-Barciela</surname><given-names>M</given-names></name><name><surname>Figuera Basso</surname><given-names>ME</given-names></name><name><surname>Valsecchi</surname><given-names>MG</given-names></name><name><surname>Hernandez-Tejero</surname><given-names>M</given-names></name><name><surname>Acosta-Herrera</surname><given-names>M</given-names></name><name><surname>D’Angiò</surname><given-names>M</given-names></name><name><surname>Baldini</surname><given-names>M</given-names></name><name><surname>Cazzaniga</surname><given-names>M</given-names></name><name><surname>Schulzky</surname><given-names>M</given-names></name><name><surname>Cecconi</surname><given-names>M</given-names></name><name><surname>Wittig</surname><given-names>M</given-names></name><name><surname>Ciccarelli</surname><given-names>M</given-names></name><name><surname>Rodríguez-Gandía</surname><given-names>M</given-names></name><name><surname>Bocciolone</surname><given-names>M</given-names></name><name><surname>Miozzo</surname><given-names>M</given-names></name><name><surname>Montano</surname><given-names>N</given-names></name><name><surname>Braun</surname><given-names>N</given-names></name><name><surname>Sacchi</surname><given-names>N</given-names></name><name><surname>Martínez</surname><given-names>N</given-names></name><name><surname>Özer</surname><given-names>O</given-names></name><name><surname>Palmieri</surname><given-names>O</given-names></name><name><surname>Faverio</surname><given-names>P</given-names></name><name><surname>Preatoni</surname><given-names>P</given-names></name><name><surname>Bonfanti</surname><given-names>P</given-names></name><name><surname>Omodei</surname><given-names>P</given-names></name><name><surname>Tentorio</surname><given-names>P</given-names></name><name><surname>Castro</surname><given-names>P</given-names></name><name><surname>Rodrigues</surname><given-names>PM</given-names></name><name><surname>Blandino Ortiz</surname><given-names>A</given-names></name><name><surname>de Cid</surname><given-names>R</given-names></name><name><surname>Ferrer</surname><given-names>R</given-names></name><name><surname>Gualtierotti</surname><given-names>R</given-names></name><name><surname>Nieto</surname><given-names>R</given-names></name><name><surname>Goerg</surname><given-names>S</given-names></name><name><surname>Badalamenti</surname><given-names>S</given-names></name><name><surname>Marsal</surname><given-names>S</given-names></name><name><surname>Matullo</surname><given-names>G</given-names></name><name><surname>Pelusi</surname><given-names>S</given-names></name><name><surname>Juzenas</surname><given-names>S</given-names></name><name><surname>Aliberti</surname><given-names>S</given-names></name><name><surname>Monzani</surname><given-names>V</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name><name><surname>Wesse</surname><given-names>T</given-names></name><name><surname>Lenz</surname><given-names>TL</given-names></name><name><surname>Pumarola</surname><given-names>T</given-names></name><name><surname>Rimoldi</surname><given-names>V</given-names></name><name><surname>Bosari</surname><given-names>S</given-names></name><name><surname>Albrecht</surname><given-names>W</given-names></name><name><surname>Peter</surname><given-names>W</given-names></name><name><surname>Romero-Gómez</surname><given-names>M</given-names></name><name><surname>D’Amato</surname><given-names>M</given-names></name><name><surname>Duga</surname><given-names>S</given-names></name><name><surname>Banales</surname><given-names>JM</given-names></name><name><surname>Hov</surname><given-names>JR</given-names></name><name><surname>Folseraas</surname><given-names>T</given-names></name><name><surname>Valenti</surname><given-names>L</given-names></name><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>Karlsen</surname><given-names>TH</given-names></name><collab>Severe Covid-19 GWAS Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Genomewide association study of severe covid-19 with respiratory failure</article-title><source>The New England Journal of Medicine</source><volume>383</volume><fpage>1522</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2020283</pub-id><pub-id pub-id-type="pmid">32558485</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagherazzi</surname><given-names>G</given-names></name><name><surname>Gusto</surname><given-names>G</given-names></name><name><surname>Clavel-Chapelon</surname><given-names>F</given-names></name><name><surname>Balkau</surname><given-names>B</given-names></name><name><surname>Bonnet</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Abo and rhesus blood groups and risk of type 2 diabetes: Evidence from the large E3N cohort study</article-title><source>Diabetologia</source><volume>58</volume><fpage>519</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1007/s00125-014-3472-9</pub-id><pub-id pub-id-type="pmid">25533388</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franchini</surname><given-names>M</given-names></name><name><surname>Lippi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The intriguing relationship between the ABO blood group, cardiovascular disease, and cancer</article-title><source>BMC Medicine</source><volume>13</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-014-0250-y</pub-id><pub-id pub-id-type="pmid">25592962</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groot</surname><given-names>HE</given-names></name><name><surname>Villegas Sierra</surname><given-names>LE</given-names></name><name><surname>Said</surname><given-names>MA</given-names></name><name><surname>Lipsic</surname><given-names>E</given-names></name><name><surname>Karper</surname><given-names>JC</given-names></name><name><surname>van der Harst</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Genetically determined ABO blood group and its associations with health and disease</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>40</volume><fpage>830</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.119.313658</pub-id><pub-id pub-id-type="pmid">31969017</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>PV</given-names></name><name><surname>O’Donnell</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Abo blood group determines plasma von Willebrand factor levels: A biologic function after all?</article-title><source>Transfusion</source><volume>46</volume><fpage>1836</fpage><lpage>1844</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2006.00975.x</pub-id><pub-id pub-id-type="pmid">17002642</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Köster</surname><given-names>J</given-names></name><name><surname>Rahmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Snakemake -- a scalable bioinformatics workflow engine</article-title><source>Bioinformatics</source><volume>28</volume><fpage>2520</fpage><lpage>2522</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts480</pub-id><pub-id pub-id-type="pmid">22908215</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurian</surname><given-names>AK</given-names></name><name><surname>Cardarelli</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Racial and ethnic differences in cardiovascular disease risk factors: A systematic review</article-title><source>Ethnicity &amp; Disease</source><volume>17</volume><fpage>143</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">17274224</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Schooling</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A phenome-wide association study of ABO blood groups</article-title><source>BMC Medicine</source><volume>18</volume><elocation-id>334</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-020-01795-4</pub-id><pub-id pub-id-type="pmid">33198801</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liumbruno</surname><given-names>GM</given-names></name><name><surname>Franchini</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hemostasis, cancer, and ABO blood group: The most recent evidence of association</article-title><source>Journal of Thrombosis and Thrombolysis</source><volume>38</volume><fpage>160</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1007/s11239-013-1027-4</pub-id><pub-id pub-id-type="pmid">24233389</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McQuillan</surname><given-names>GM</given-names></name><name><surname>Kruszon-Moran</surname><given-names>D</given-names></name><name><surname>Kottiri</surname><given-names>BJ</given-names></name><name><surname>Curtin</surname><given-names>LR</given-names></name><name><surname>Lucas</surname><given-names>JW</given-names></name><name><surname>Kington</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: Data from NHANES III, 1988-1994</article-title><source>American Journal of Public Health</source><volume>94</volume><fpage>1952</fpage><lpage>1958</lpage><pub-id pub-id-type="doi">10.2105/ajph.94.11.1952</pub-id><pub-id pub-id-type="pmid">15514236</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Nordjylland</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Regioner i Danmark</article-title><ext-link ext-link-type="uri" xlink:href="https://rn.dk/genveje/fakta-om-nordjylland/regioner-i-danmark">https://rn.dk/genveje/fakta-om-nordjylland/regioner-i-danmark</ext-link><date-in-citation iso-8601-date="2022-08-31">August 31, 2022</date-in-citation></element-citation></ref><ref id="bib23"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>MK</given-names></name><name><surname>Eriksson</surname><given-names>R</given-names></name><name><surname>Pedersen</surname><given-names>HK</given-names></name><name><surname>Collin</surname><given-names>C</given-names></name><name><surname>Reguant</surname><given-names>R</given-names></name><name><surname>Simon</surname><given-names>C</given-names></name><name><surname>Sørup</surname><given-names>FKH</given-names></name><name><surname>Damgaard</surname><given-names>KA</given-names></name><name><surname>Birch</surname><given-names>AM</given-names></name><name><surname>Larsen</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>AP</given-names></name><name><surname>Kirstine Belling</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>A unidirectional mapping of ICD-8 to ICD-10 codes, for harmonized longitudinal analysis of diseases</data-title><source>Under Rev</source></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The ABO blood group distribution and pulmonary tuberculosis</article-title><source>Journal of Clinical and Diagnostic Research</source><volume>6</volume><fpage>943</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.7860/JCDR.2012.4370.2298</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravn</surname><given-names>V</given-names></name><name><surname>Dabelsteen</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Tissue distribution of histo-blood group antigens</article-title><source>APMIS</source><volume>108</volume><fpage>1</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0463.2000.d01-1.x</pub-id><pub-id pub-id-type="pmid">10698081</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teuwen</surname><given-names>LA</given-names></name><name><surname>Geldhof</surname><given-names>V</given-names></name><name><surname>Pasut</surname><given-names>A</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19: The vasculature unleashed</article-title><source>Nature Reviews. Immunology</source><volume>20</volume><fpage>389</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0343-0</pub-id><pub-id pub-id-type="pmid">32439870</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasan</surname><given-names>SK</given-names></name><name><surname>Rostgaard</surname><given-names>K</given-names></name><name><surname>Majeed</surname><given-names>A</given-names></name><name><surname>Ullum</surname><given-names>H</given-names></name><name><surname>Titlestad</surname><given-names>KE</given-names></name><name><surname>Pedersen</surname><given-names>OBV</given-names></name><name><surname>Erikstrup</surname><given-names>C</given-names></name><name><surname>Nielsen</surname><given-names>KR</given-names></name><name><surname>Melbye</surname><given-names>M</given-names></name><name><surname>Nyrén</surname><given-names>O</given-names></name><name><surname>Hjalgrim</surname><given-names>H</given-names></name><name><surname>Edgren</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ABO blood group and risk of thromboembolic and arterial disease: A study of 1.5 million blood donors</article-title><source>Circulation</source><volume>133</volume><fpage>1449</fpage><lpage>1457</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.017563</pub-id><pub-id pub-id-type="pmid">26939588</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ver Hoef</surname><given-names>JM</given-names></name><name><surname>Boveng</surname><given-names>PL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Quasi-poisson vs. negative binomial regression: How should we model overdispersed count data?</article-title><source>Ecology</source><volume>88</volume><fpage>2766</fpage><lpage>2772</lpage><pub-id pub-id-type="doi">10.1890/07-0043.1</pub-id><pub-id pub-id-type="pmid">18051645</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westergaard</surname><given-names>D</given-names></name><name><surname>Moseley</surname><given-names>P</given-names></name><name><surname>Sørup</surname><given-names>FKH</given-names></name><name><surname>Baldi</surname><given-names>P</given-names></name><name><surname>Brunak</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Population-wide analysis of differences in disease progression patterns in men and women</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>666</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08475-9</pub-id><pub-id pub-id-type="pmid">30737381</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolpin</surname><given-names>BM</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Gross</surname><given-names>M</given-names></name><name><surname>Helzlsouer</surname><given-names>K</given-names></name><name><surname>Bueno-de-Mesquita</surname><given-names>HB</given-names></name><name><surname>Steplowski</surname><given-names>E</given-names></name><name><surname>Stolzenberg-Solomon</surname><given-names>RZ</given-names></name><name><surname>Arslan</surname><given-names>AA</given-names></name><name><surname>Jacobs</surname><given-names>EJ</given-names></name><name><surname>Lacroix</surname><given-names>A</given-names></name><name><surname>Petersen</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Allen</surname><given-names>NE</given-names></name><name><surname>Amundadottir</surname><given-names>L</given-names></name><name><surname>Anderson</surname><given-names>G</given-names></name><name><surname>Boutron-Ruault</surname><given-names>MC</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Canzian</surname><given-names>F</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Clipp</surname><given-names>S</given-names></name><name><surname>Gaziano</surname><given-names>JM</given-names></name><name><surname>Giovannucci</surname><given-names>EL</given-names></name><name><surname>Hallmans</surname><given-names>G</given-names></name><name><surname>Hankinson</surname><given-names>SE</given-names></name><name><surname>Hoover</surname><given-names>RN</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Hutchinson</surname><given-names>A</given-names></name><name><surname>Jacobs</surname><given-names>K</given-names></name><name><surname>Kooperberg</surname><given-names>C</given-names></name><name><surname>Lynch</surname><given-names>SM</given-names></name><name><surname>Mendelsohn</surname><given-names>JB</given-names></name><name><surname>Michaud</surname><given-names>DS</given-names></name><name><surname>Overvad</surname><given-names>K</given-names></name><name><surname>Patel</surname><given-names>AV</given-names></name><name><surname>Rajkovic</surname><given-names>A</given-names></name><name><surname>Sanchéz</surname><given-names>MJ</given-names></name><name><surname>Shu</surname><given-names>XO</given-names></name><name><surname>Slimani</surname><given-names>N</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Tobias</surname><given-names>GS</given-names></name><name><surname>Trichopoulos</surname><given-names>D</given-names></name><name><surname>Vineis</surname><given-names>P</given-names></name><name><surname>Virtamo</surname><given-names>J</given-names></name><name><surname>Wactawski-Wende</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Zeleniuch-Jacquotte</surname><given-names>A</given-names></name><name><surname>Hartge</surname><given-names>P</given-names></name><name><surname>Fuchs</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Pancreatic cancer risk and ABO blood group alleles: Results from the pancreatic cancer cohort Consortium</article-title><source>Cancer Research</source><volume>70</volume><fpage>1015</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2993</pub-id><pub-id pub-id-type="pmid">20103627</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Gifford</surname><given-names>A</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Campbell</surname><given-names>H</given-names></name><name><surname>Varley</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Carroll</surname><given-names>R</given-names></name><name><surname>Bastarache</surname><given-names>L</given-names></name><name><surname>Denny</surname><given-names>JC</given-names></name><name><surname>Theodoratou</surname><given-names>E</given-names></name><name><surname>Wei</surname><given-names>WQ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mapping icd-10 and icd-10-cm codes to phecodes: Workflow development and initial evaluation</article-title><source>JMIR Medical Informatics</source><volume>7</volume><elocation-id>e14325</elocation-id><pub-id pub-id-type="doi">10.2196/14325</pub-id><pub-id pub-id-type="pmid">31553307</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>K</given-names></name><name><surname>Lewis</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Immortal time bias in observational studies</article-title><source>JAMA</source><volume>325</volume><fpage>686</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.9151</pub-id><pub-id pub-id-type="pmid">33591334</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83116.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Boonstra</surname><given-names>Philip</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>University of Michigan</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.09.23.22280292" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.23.22280292"/></front-stub><body><p>This important retrospective analysis of nearly 500,000 hospitalized Danish patients sheds light on the possible relationships between blood type and susceptibility to a host of diseases. The Danish National Patient Register is a compelling data source, and the statistical methodology is solid. The findings reported herein provide evidence, supporting information, and potential hypotheses for researchers interested in the causes and etiology of diseases as they relate to blood type.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83116.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Boonstra</surname><given-names>Philip</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>University of Michigan</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Boonstra</surname><given-names>Philip</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>University of Michigan</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.09.23.22280292">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.09.23.22280292v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Associations of ABO and Rhesus D Blood Groups with Phenome-Wide Disease Incidence: A 41-year Retrospective Cohort Study of 482,914 Patients&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Philip Boonstra as Reviewing Editor and Reviewer #3, and the evaluation has been overseen by a Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Reviewers 1 and 3 both point out an issue regarding the A and O subgroups dominating the analyses due to their sample size. This seems to be a very important caveat to include in the comparison of the number of statistically significant findings per blood group.</p><p>2) Reviewer 1 comments on the lack of adjustment for patient ethnicity as a confounder (or a surrogate for other confounders). Please engage with this comment, which may involve explaining why this is unlikely, or which may involve actually trying to incorporate patient ethnicity into your models.</p><p>3) All of the reviewers raise many other good points in their Comments to the Authors, which I encourage you to read and engage with, potentially adjusting your analyses if you believe appropriate.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>This study aims to address the important question of how different blood types are related to disease risk and age at diagnosis.</p><p>However, a major concern is that as per the comments in the public review, the lack of adjustment for confounding due to ethnicity represents a highly substantial limitation of this work. While it is briefly mentioned in the manuscript, this is a very major limitation that leads to very limited interpretability of the results. Incorporating ethnicity as a covariate into the analyses would be crucial.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Abstract/Intro</p><p>– &quot;we determined the uniqueness&quot; is a bit vague, could you more explicitly say you perform tests with A, AB, B, and O blood groups each as reference group as opposed to only O as the reference group?</p><p>– &quot;diagnosis-wide&quot; or &quot;disease-wide&quot; was used but perhaps more accurate to say &quot;phenome wide&quot; as in the title? Both disease-wide and diagnosis-wide are also used in the introduction before phecodes are introduced, and consistency might be better here.</p><p>– Age of disease onset specifically, not just disease onset, and perhaps age at first diagnosis is the most accurate (as is used in the introduction).</p><p>Methodological considerations</p><p>– ICD9 wasn't used? Most of the phecode mapping was done in ICD9/ICD10. Am I understanding ref 16 is in preparation? It would be important to describe how this is done and how it may bias your phecodes, particularly if ref 16 is not pre-printed yet. A good sanity check is how the prevalence/incidence of a handful of traits with this mapping compares to any other population-wide prevalence/incidence measures.</p><p>– It would be great to see a sensitivity analysis using either a mixed model to adjust for cryptic relatedness, close family structure, and population structure (presuming like other countries, the DNPR has many relatives). This may not statistically work with the quasi-Poisson model, so perhaps just restricting it to &lt;3 degree individuals and comparing findings (of course this will decrease power, but nice to see if some of the main findings remain).</p><p>– I see it in the limitations, but please comment earlier in the manuscript on who gets a blood group determination in the hospital (e.g. people who made need a transplant sooner). Is it possible to characterize the disease prevalence in the subsection of the DNPR with a blood type and without so you can identify any major disease group biases?</p><p>– Was a power calculation used to determine the need for 100 cases?</p><p>– How is emigration recorded? National registers?</p><p>– The interquartile range would be a better descriptor of follow-up time rather than just the maximum (41 years) in the methods and in the limitations section.</p><p>– Why use a log-linear quasi-Poisson regression to estimate incidence rate ratios as opposed to logistic regression and odds ratios? It could be a valuable addition to the paper to provide odds ratios as well.</p><p>– It's good to adjust for ABO and RhD when testing RhD and ABO respectively, but is it possible to use interaction terms and consider these as well?</p><p>– It's great to use birth year to adjust for any &quot;cohort effects&quot; in society over time. Is attained age the age at end of the study period? Wouldn't birth year and attained age be too highly correlated to use both in the model? What is the rationale for using cubic splines for these variables rather than the numerical variables themselves? I see from the code that 20-year increments were used for the knots, any rationale for this methodology would be helpful.</p><p>– By excluding patients assigned a phecode at the start of the DNPR, would these be people who had the diagnosis previously and were recorded upon the inauguration of the register? Is there any kind of washout period you are using to define &quot;start&quot; of the DNPR?</p><p>– What is the ancestral breakdown of the cohort? Mostly European ancestries? While our current labels for genetic ancestry are quite rough, I think this is an important piece of information given the different distributions of blood groups across global populations.</p><p>– Excellent availability of code and summary data for tables/graphs.</p><p>Results</p><p>– The audience may be less interested in the number of significant phecodes and more in patterns. It could be good to comment on the shared phecodes between the 50, 38, 11, 53, and 28 found. What large-scale disease groupings (phewas disease categories) do these tend to fall in? Does one blood group have far more cardiovascular phecodes than another? Are any phecodes significant for more than 3 blood groups? Etc.</p><p>– Personally, I prefer p-values in scientific notation rather than &lt;0.001 but I understand Table 2 is a lot of data to present.</p><p>– The figures could benefit from larger labels for readability.</p><p>– For the Manhattan plots, it would be good to specify -log10 FDR transformed adjusted p-values on the y-axis in addition to the figure legend.</p><p>– Were any blood groups associated with an earlier onset of outcomes?</p><p>Discussion</p><p>– What was used to identify &quot;novel associations&quot;? A systematic literature review? Comparison to Dahlén? I would refrain from using novel unless you define specifically how it was determined to be novel.</p><p>– A systematic comparison with what seems to be the closest study, Dahlén et al., would be beneficial as a type of replication.</p><p>– I would refrain from using the term linkage in the discussion as that may lead the reader to think of chromosomal linkage, but I think the authors mean a causal association.</p><p>– I don't think the findings support the discussion point on the selective pressure.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1. Could the authors justify why choosing to fit separate models comparing one blood type against all others, e.g. A vs. all others then AB vs. all others, is the more sensible choice than fitting one model that jointly tests for A vs. AB vs. B vs. O? I understand that there are various interpretative and statistical challenges to both, but fitting separate models is not internally consistent. The 'A vs. all others' model implicitly assumes that there is no difference in incidence in the AB, B, and O groups, but then the next model ('AB vs. all others') makes a different assumption, namely that there is no difference in incidence in the A, B, and O groups.</p><p>2. A natural limitation to this analysis is that there are more statistically significant findings in the O and A blood groups because they are the more prevalent groups, and statistical significance is driven by sample size. In this sense, it would be interesting if there were a way to account for the differences in sample size between the blood groups. Is it possible to investigate whether any of the groups have disproportionately more statistically significant findings after accounting for sample size?</p><p>3. Page 6, line 124: I think the use of the word 'confounder' here is not quite right in the technical sense, as I do not read this sentence to be claiming that sex is influencing blood type.</p><p>4. Regarding the legend for Figure 2:</p><p>a. It should have triangles rather than circles. Assuming this plot was made in ggplot2, this can be done using the override.aes argument in the guides function.</p><p>b. it would be helpful to show more than 3 values on the legend.</p><p>c. It would be helpful to use the same scale across the subfigures. What I mean is, in the bloodgroup AB figure, there is no discernible difference in size between a 1.1 and a 4.0 rate ratio.</p><p>d. I realize this is very pedantic but I believe the legend is technically not showing rate ratios but rather max(rate_ratio, 1/rate_ratio).</p><p>5. Do the authors have any intuition why Figure 1 is bimodal? My interpretation of this figure is that, among those who were hospitalized in Denmark between 2006 and 2018, the plurality was born either in the immediate post-WW2 era (makes sense to me) or the 80s (doesn't make as much sense to me).</p><p>6. Page 7, line 152: reference 20 is not related to FDR. Can the authors provide a reference for their specific approach to controlling FDR?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83116.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Reviewers 1 and 3 both point out an issue regarding the A and O subgroups dominating the analyses due to their sample size. This seems to be a very important caveat to include in the comparison of the number of statistically significant findings per blood group.</p></disp-quote><p>This has now been mentioned in the lines where the number of statistically significant findings per blood groups are mentioned (lines 191-194). Further, a supplemental analysis has been included where blood group O is used as the reference (Supplementary files 6–7.</p><disp-quote content-type="editor-comment"><p>2) Reviewer 1 comments on the lack of adjustment for patient ethnicity as a confounder (or a surrogate for other confounders). Please engage with this comment, which may involve explaining why this is unlikely, or which may involve actually trying to incorporate patient ethnicity into your models.</p></disp-quote><p>We unfortunately do not have access to information on ethnicity. We have further elaborated on this limitation in the manuscript and pointed out that the Danish population is quite homogenous why this is less of a concern in our study as compared with studies of populations with more admixed origin (lines 341-349). For a more detailed discussion on this please see our response to the reviewers’ comments.</p><disp-quote content-type="editor-comment"><p>3) All of the reviewers raise many other good points in their Comments to the Authors, which I encourage you to read and engage with, potentially adjusting your analyses if you believe appropriate.</p></disp-quote><p>We have engaged with all the comments and have changed the manuscript and figures accordingly.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>This study aims to address the important question of how different blood types are related to disease risk and age at diagnosis.</p><p>However, a major concern is that as per the comments in the public review, the lack of adjustment for confounding due to ethnicity represents a highly substantial limitation of this work. While it is briefly mentioned in the manuscript, this is a very major limitation that leads to very limited interpretability of the results. Incorporating ethnicity as a covariate into the analyses would be crucial.</p></disp-quote><p>We agreed that ethnicity may introduce bias in the analysis of some diseases. We have now further elaborated on this limitation in lines 341-349. Unfortunately, we do not have information on ethnicity, and therefore an analysis adjusting for ethnicity is not possible with the available data. While we agree that ethnicity is a concern, it should be noted that ethnicity will only introduce confounding for the analysis of diagnosis which are more common for certain ethnicities and where at the same time the distribution of the ABO/RhD blood groups are different between ethnicities. This may e.g. be the case for infectious diseases, cardiovascular diseases and bleeding disorders as has now been mentioned in the limitations. Further, the Danish population is very homogeneous (approximately 94% have European origin). Therefore, a potential bias from not being able to adjust for ethnicity will be less distinct in our study. In Supplement Figure 1, we have now provided a graph showing the ancestry of the complete Danish population, the Capital Region of Denmark, and Region Zealand from 2008-2016 (Supplemenary file 1). From the graph it can be seen that approximately 90% of the population in the Capital Region and 97% of the Region Zealand population were of European origin. This information has now been added in the method section lines 99-102.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Abstract/Intro</p><p>– &quot;we determined the uniqueness&quot; is a bit vague, could you more explicitly say you perform tests with A, AB, B, and O blood groups each as reference group as opposed to only O as the reference group?</p></disp-quote><p>The formulation has now been changed to “we determined the incidence rate ratios for each individual ABO blood group relative to all other ABO blood groups…” (lines 37-38).</p><disp-quote content-type="editor-comment"><p>– &quot;diagnosis-wide&quot; or &quot;disease-wide&quot; was used but perhaps more accurate to say &quot;phenome wide&quot; as in the title? Both disease-wide and diagnosis-wide are also used in the introduction before phecodes are introduced, and consistency might be better here.</p></disp-quote><p>We have chosen not to use the term “phenome wide” in the manuscript text because “phenome wide” without the mentioning of disease is to be understood as a PheWAS analysis where genetic information of a specific SNP is used. The title is combining “phenome-wide” with “disease incidence” to underline that it is not a classic PheWAS study. As suggested by the reviewer we have now consistently used “disease-wide” in the introduction.</p><disp-quote content-type="editor-comment"><p>– Age of disease onset specifically, not just disease onset, and perhaps age at first diagnosis is the most accurate (as is used in the introduction).</p></disp-quote><p>We agree that age at first diagnosis is the most accurate formulation. This has now been changed throughout the manuscript.</p><disp-quote content-type="editor-comment"><p>Methodological considerations</p><p>– ICD9 wasn't used? Most of the phecode mapping was done in ICD9/ICD10. Am I understanding ref 16 is in preparation? It would be important to describe how this is done and how it may bias your phecodes, particularly if ref 16 is not pre-printed yet. A good sanity check is how the prevalence/incidence of a handful of traits with this mapping compares to any other population-wide prevalence/incidence measures.</p></disp-quote><p>ICD9 codes was never used in Denmark. Ref 16 is currently under review. I have received a copy of the manuscript by the authors which I have now uploaded as a “related manuscript file” for the reviewers to see. The authors do unfortunately not wish to make it available as preprint.</p><disp-quote content-type="editor-comment"><p>– It would be great to see a sensitivity analysis using either a mixed model to adjust for cryptic relatedness, close family structure, and population structure (presuming like other countries, the DNPR has many relatives). This may not statistically work with the quasi-Poisson model, so perhaps just restricting it to &lt;3 degree individuals and comparing findings (of course this will decrease power, but nice to see if some of the main findings remain).</p></disp-quote><p>This is indeed an interesting suggestion. Unfortunately, we do not have access to information on population or family structure. However, we do not believe that family structure would impose a significant amount of bias given the large sample size. As mentioned in the limitation’s ethnicity may however impose a bias which have now been further elaborated in the limitations section.</p><disp-quote content-type="editor-comment"><p>– I see it in the limitations, but please comment earlier in the manuscript on who gets a blood group determination in the hospital (e.g. people who made need a transplant sooner). Is it possible to characterize the disease prevalence in the subsection of the DNPR with a blood type and without so you can identify any major disease group biases?</p></disp-quote><p>We have now commented earlier on in the manuscript on the kinds of patients which were included in the study (lines 99-100). Further, we have in the limitation elaborated on what this means for generalizability (lines 336-339). With the available data is it unfortunately not possible to identify any major disease group differences between the hospitalized patients with a blood group determination and those without.</p><disp-quote content-type="editor-comment"><p>– Was a power calculation used to determine the need for 100 cases?</p></disp-quote><p>A power calculation was not used. Similarly to the study by Dahlén et al. the number of cut-off cases was arbitrarily picked. We have now changed the formulation in line 111-112 so that is cannot be understood as if a power calculation had been done for each of the 5x1300 analysis.</p><disp-quote content-type="editor-comment"><p>– How is emigration recorded? National registers?</p></disp-quote><p>Yes. This information has now been added to the manuscript (line 104).</p><disp-quote content-type="editor-comment"><p>– The interquartile range would be a better descriptor of follow-up time rather than just the maximum (41 years) in the methods and in the limitations section.</p></disp-quote><p>In the methods and limitation we referred to the length of the study period which is the maximum length of follow-up. The median and interquartile range of follow-up time in the cohort is given in Table 1.</p><disp-quote content-type="editor-comment"><p>– Why use a log-linear quasi-Poisson regression to estimate incidence rate ratios as opposed to logistic regression and odds ratios? It could be a valuable addition to the paper to provide odds ratios as well.</p></disp-quote><p>A logistic regression would not take time-to-event into account. Thus, incorporating person-time using a log-linear Poisson regression enriches the analysis as compared with a logistic regression.</p><disp-quote content-type="editor-comment"><p>– It's good to adjust for ABO and RhD when testing RhD and ABO respectively, but is it possible to use interaction terms and consider these as well?</p></disp-quote><p>Similar to the study by Dahlén et al. we chose not to consider interactions between the ABO and RhD blood groups as there is little evidence that such interaction exists.</p><disp-quote content-type="editor-comment"><p>– It's great to use birth year to adjust for any &quot;cohort effects&quot; in society over time. Is attained age the age at end of the study period? Wouldn't birth year and attained age be too highly correlated to use both in the model? What is the rationale for using cubic splines for these variables rather than the numerical variables themselves? I see from the code that 20-year increments were used for the knots, any rationale for this methodology would be helpful.</p></disp-quote><p>Attained age is not the age at the end of the study period. If so attained age and birth year would indeed be highly correlated. Attained age is the underlying person-time. In a classic logistic regression time is not incorporated. However, we are doing a time-to-event study using a log-linear Possion regression incorporating person-time. Attained age is thus the age of each individual at each time period in the study. Thus, we are comparing individuals of the same age over time. As explained in the methods section, attained age is divide into 1-year time intervals and used as the underlying time.</p><p>We did use the numerical variables in the models however instead of assuming linear relationships we used cubic splines to allow flexible modeling which better adjusts for potential non-linear relationships. For a more elaborated discussion on the benefits modelling using restricted cubic splines the reviewer is referred to: Gauthier, J., Q. V. Wu, and T. A. Gooley. &quot;Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians.&quot; <italic>Bone marrow transplantation</italic> 55.4 (2020): 675-680.</p><disp-quote content-type="editor-comment"><p>– By excluding patients assigned a phecode at the start of the DNPR, would these be people who had the diagnosis previously and were recorded upon the inauguration of the register? Is there any kind of washout period you are using to define &quot;start&quot; of the DNPR?</p></disp-quote><p>This is likely to be people who had the diagnosis previously which was then registered at time the registry was created. Few is also likely to be individuals who got the diagnosis at the very start of the registry. Because this is unknown, we chose to exclude these patients from the analysis as this information was regarded too noisy. There is no wash-out period. The “start” of the DNPR is defined as the official start of the registry. Few patient were excluded from this procedure and thus the effect on the analysis is very limited.</p><disp-quote content-type="editor-comment"><p>– What is the ancestral breakdown of the cohort? Mostly European ancestries? While our current labels for genetic ancestry are quite rough, I think this is an important piece of information given the different distributions of blood groups across global populations.</p></disp-quote><p>The Danish population is very homogeneous and mostly of European ancestry. We have now added a table in Supplementary file 1 showing the ancestral distribution in Denmark in the inclusion period. We do unfortunately not have any information available on ancestry or ethnicity of the study sample. This fact has now been further elaborated in the limitations section lines 341-348.</p><disp-quote content-type="editor-comment"><p>– Excellent availability of code and summary data for tables/graphs.</p></disp-quote><p>Thanks. We have tried to make the analysis code easy accessible to allow for replication in other cohorts.</p><disp-quote content-type="editor-comment"><p>Results</p><p>– The audience may be less interested in the number of significant phecodes and more in patterns. It could be good to comment on the shared phecodes between the 50, 38, 11, 53, and 28 found. What large-scale disease groupings (phewas disease categories) do these tend to fall in? Does one blood group have far more cardiovascular phecodes than another? Are any phecodes significant for more than 3 blood groups? Etc.</p></disp-quote><p>We have now commented on the phewas disease groupings of the blood groups (lines 198-201).</p><disp-quote content-type="editor-comment"><p>– Personally, I prefer p-values in scientific notation rather than &lt;0.001 but I understand Table 2 is a lot of data to present.</p></disp-quote><p>This was also something we considered. However, we decided that we would rather direct the reader’s attention to the confidence intervals than the p-value. Therefore, we used the &lt;0.001 notation.</p><disp-quote content-type="editor-comment"><p>– The figures could benefit from larger labels for readability.</p></disp-quote><p>Larger labels have now been added to the figures.</p><disp-quote content-type="editor-comment"><p>– For the Manhattan plots, it would be good to specify -log10 FDR transformed adjusted p-values on the y-axis in addition to the figure legend.</p></disp-quote><p>This has now been specified on the y-axis.</p><disp-quote content-type="editor-comment"><p>– Were any blood groups associated with an earlier onset of outcomes?</p></disp-quote><p>In table 3 we show the findings from the analysis on the ABO and RhD blood groups association with age at the first diagnosis.</p><disp-quote content-type="editor-comment"><p>Discussion</p><p>– What was used to identify &quot;novel associations&quot;? A systematic literature review? Comparison to Dahlén? I would refrain from using novel unless you define specifically how it was determined to be novel.</p></disp-quote><p>We did a literature search ourselves but agree that without a reference to a published systematic literature review the term novel should not be used. We have now removed the term “novel” lines 266 and 268.</p><disp-quote content-type="editor-comment"><p>– A systematic comparison with what seems to be the closest study, Dahlén et al., would be beneficial as a type of replication.</p></disp-quote><p>We agree with the reviewer that such comparison would be beneficial. However, a systematic comparison would be very comprehensive, and we believe it would be more appropriate as a manuscript on its own. In the discussion we have instead chosen to discuss a few selected findings some of which have also been found in the study by Dahlén et al. as indicated by a reference to the study by Dahlén et al. For example, we highlight associations of pancreatic cancer, gastroduodenal ulcers, type 2 diabetes, and cardiovascular diseases which was also observed by Dahlén et al. Lastly, it should be noted that the two studies cannot be compared directly as Dahlén et al. used blood groups O as the reference and we used all other blood groups as the reference.</p><disp-quote content-type="editor-comment"><p>– I would refrain from using the term linkage in the discussion as that may lead the reader to think of chromosomal linkage, but I think the authors mean a causal association.</p></disp-quote><p>The term linkage has now been changed to relationship (line 273).</p><disp-quote content-type="editor-comment"><p>– I don't think the findings support the discussion point on the selective pressure.</p></disp-quote><p>We agree, this point has now been removed from the discussion and conclusion.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1. Could the authors justify why choosing to fit separate models comparing one blood type against all others, e.g. A vs. all others then AB vs. all others, is the more sensible choice than fitting one model that jointly tests for A vs. AB vs. B vs. O? I understand that there are various interpretative and statistical challenges to both, but fitting separate models is not internally consistent. The 'A vs. all others' model implicitly assumes that there is no difference in incidence in the AB, B, and O groups, but then the next model ('AB vs. all others') makes a different assumption, namely that there is no difference in incidence in the A, B, and O groups.</p></disp-quote><p>The aim of the study was to determine how each individual ABO blood group is distinct from all other ABO blood groups in terms of disease susceptibility. This question can only be answered by fitting separate models defining the patients as either having the blood group under study or not. An alternative, which would answer a different research question, would be to do a pairwise comparison between each ABO blood group would require 8x1,312 analyses (see response 1 to reviewer #1s comment). We do not believe that one model which jointly tests for all pair-wise comparisons can be fitted, the model would need to define a reference which in previous studies have been blood group O. The research question which has been asked in previous studies is thus how does blood group A, B and AB differ from blood group O in terms of disease susceptibility, respectively. We believe it to be more informative to ask how each blood group differs from all the other blood groups. However, we agree with the reviewer that this has its limitations because of the difference in the frequency of the individual ABO blood groups. We have now added a Supplementary Analysis where blood group O has been used as the reference (lines 145-147). The results of the supplemental analysis are presented in Supplementary files 6–7.</p><disp-quote content-type="editor-comment"><p>2. A natural limitation to this analysis is that there are more statistically significant findings in the O and A blood groups because they are the more prevalent groups, and statistical significance is driven by sample size. In this sense, it would be interesting if there were a way to account for the differences in sample size between the blood groups. Is it possible to investigate whether any of the groups have disproportionately more statistically significant findings after accounting for sample size?</p></disp-quote><p>We agree that this is a natural limitation to any study concerning blood groups and we have now commented on this in line 192-195. The only way to be able to better find associations for the less prevalent blood groups would be to include more patients, potentially by conducting a similar study combining cohorts from several countries to increase the power. We do not know of a way to determine if any of the blood groups have disproportionately more statistically significant findings while accounting for sample size.</p><disp-quote content-type="editor-comment"><p>3. Page 6, line 124: I think the use of the word 'confounder' here is not quite right in the technical sense, as I do not read this sentence to be claiming that sex is influencing blood type.</p></disp-quote><p>We agree with the reviewer that this was an incorrect formulation. We have now changed the statement.</p><disp-quote content-type="editor-comment"><p>4. Regarding the legend for Figure 2:</p><p>a. It should have triangles rather than circles. Assuming this plot was made in ggplot2, this can be done using the override.aes argument in the guides function.</p></disp-quote><p>We thank the reviewer for this tip. The circles have now been replaced by triangles.</p><disp-quote content-type="editor-comment"><p>b. it would be helpful to show more than 3 values on the legend.</p></disp-quote><p>We have now added two more legends so that five values are shown. However, for the comparison of the IRRs the readers should instead use table 2.</p><disp-quote content-type="editor-comment"><p>c. It would be helpful to use the same scale across the subfigures. What I mean is, in the bloodgroup AB figure, there is no discernible difference in size between a 1.1 and a 4.0 rate ratio.</p></disp-quote><p>We have now applied the same legends in all plots.</p><disp-quote content-type="editor-comment"><p>d. I realize this is very pedantic but I believe the legend is technically not showing rate ratios but rather max(rate_ratio, 1/rate_ratio).</p></disp-quote><p>This is correct. It is showing the rate ratio if rate ratio &gt;= 1 and 1/rate ratio if the rate ratio &lt;1. This makes it possible to compare the sizes of the rate ratios for both positive and negative associations. The direction of the triangles shows if it is a positive or inverse association as mentioned in the figure text.</p><disp-quote content-type="editor-comment"><p>5. Do the authors have any intuition why Figure 1 is bimodal? My interpretation of this figure is that, among those who were hospitalized in Denmark between 2006 and 2018, the plurality was born either in the immediate post-WW2 era (makes sense to me) or the 80s (doesn't make as much sense to me).</p></disp-quote><p>We agree with the reviewers first point. The reason that the distribution is bimodal is likely because the older population will be hospitalized in the inclusion period corresponding to the first peak. The second peak is likely caused by pregnant women who would be hospitalized when given birth and who commonly have their blood type determined in the hospital.</p><disp-quote content-type="editor-comment"><p>6. Page 7, line 152: reference 20 is not related to FDR. Can the authors provide a reference for their specific approach to controlling FDR?</p></disp-quote><p>Thanks for spotting this error. We have now also added a reference to the specific approach used to control for FDR.</p></body></sub-article></article>